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Inhibition of mitochondrial complex I reverses
NOTCH1-driven metabolic reprogramming in
T-cell acute lymphoblastic leukemia
Natalia Baran 1, Alessia Lodi2, Yogesh Dhungana3, Shelley Herbrich1, Meghan Collins 2, Shannon Sweeney2,
Renu Pandey2, Anna Skwarska1, Shraddha Patel1, Mathieu Tremblay4, Vinitha Mary Kuruvilla1, Antonio Cavazos1,
Mecit Kaplan 5, Marc O. Warmoes6, Diogo Troggian Veiga7, Ken Furudate 1,8, Shanti Rojas-Sutterin4,
Andre Haman4, Yves Gareau4, Anne Marinier 4, Helen Ma1, Karine Harutyunyan1, May Daher5,
Luciana Melo Garcia5, Gheath Al-Atrash5, Sujan Piya 1, Vivian Ruvolo1, Wentao Yang9,
Sriram Saravanan Shanmugavelandy10, Ningping Feng11, Jason Gay11, Di Du 6, Jun J. Yang 9, Fieke W. Hoff1,
Marcin Kaminski 12, Katarzyna Tomczak13, R. Eric Davis 14, Daniel Herranz 15, Adolfo Ferrando 16,
Elias J. Jabbour1, M. Emilia Di Francesco17, David T. Teachey 18, Terzah M. Horton 19, Steven Kornblau 1,
Katayoun Rezvani5, Guy Sauvageau4, Mihai Gagea 20, Michael Andreeff 1, Koichi Takahashi 1,
Joseph R. Marszalek11, Philip L. Lorenzi 6, Jiyang Yu 21, Stefano Tiziani2, Trang Hoang4,22 &
Marina Konopleva 1 ✉

T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in
NOTCH1 that facilitate glutamine oxidation. Here we identify oxidative phosphorylation
(OxPhos) as a critical pathway for leukemia cell survival and demonstrate a direct relationship between NOTCH1, elevated OxPhos gene expression, and acquired chemoresistance
in pre-leukemic and leukemic models. Disrupting OxPhos with IACS-010759, an inhibitor of
mitochondrial complex I, causes potent growth inhibition through induction of metabolic
shut-down and redox imbalance in NOTCH1-mutated and less so in NOTCH1-wt T-ALL cells.
Mechanistically, inhibition of OxPhos induces a metabolic reprogramming into glutaminolysis. We show that pharmacological blockade of OxPhos combined with inducible knockdown of glutaminase, the key glutamine enzyme, confers synthetic lethality in mice harboring
NOTCH1-mutated T-ALL. We leverage on this synthetic lethal interaction to demonstrate that
IACS-010759 in combination with chemotherapy containing L-asparaginase, an enzyme that
uncovers the glutamine dependency of leukemic cells, causes reduced glutaminolysis and
profound tumor reduction in pre-clinical models of human T-ALL. In summary, this metabolic
dependency of T-ALL on OxPhos provides a rational therapeutic target.

A full list of author afﬁliations appears at the end of the paper.
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T

-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia, requiring intensive chemotherapy
regimens1,2. The backbone of standard of care chemotherapy for T-ALL includes vincristine, dexamethasone, and Lasparaginase (VXL)3,4. Despite improved cure rates in pediatric
T-ALL, relapsed disease occurs in 40% of adult primary T-ALL
patients and carries a poor prognosis1,2. At the molecular level,
T-ALL is associated with abnormalities in oncogenic transcription factors5,6, with the most frequent activating mutations in
NOTCH1 that lead to upregulation of the pro-survival
NOTCH1 signaling7–9 and mutations in FBXW7 gene, which is
similar to mutations in NOTCH1 PEST domain, results in
increased ICN1 protein stability, often co-occurring with mutations in NOTCH110–12. NOTCH1 activation supports differentiation of hematopoietic progenitors toward thymocytes and
activates multiple anabolic pathways required for cell growth,
proliferation, and survival of both healthy and leukemic
T-cells6,7,13. Thus, targeting NOTCH1 and its downstream
effectors is an attractive therapeutic approach in T-ALL14–16.
However, the development of NOTCH1 inhibitors remains
challenging, due to acquired resistance and poor tolerability, so
targeting metabolic pathways downstream of NOTCH1 may offer
an alternative therapeutic approach.
Leukemia cells depend on oxidative phosphorylation (OxPhos)
to meet their energetic and biosynthetic demands17–27. Phenformin, a mitochondrial complex I/OxPhos inhibitor (OxPhos-i),
reduced disease burden in preclinical T-ALL models and
improved overall survival (OS)25. IACS-010759, a more potent
and speciﬁc small-molecule complex I inhibitor, has been investigated in clinical trials of acute myeloid leukemia (AML) and
advanced cancers (NCT03291938, NCT02882321)28. Glutaminolysis is another metabolic feature of T-ALL and AML that is
crucial for anaplerosis, biosynthetic processes, and cellular redox
maintenance29,30. Based on promising preclinical evidence of
antileukemic activity, the glutaminase inhibitor (GLS-i) CB-839 is
being investigated in ongoing clinical trials31. Also, part of the
efﬁcacy of L-asparaginase against T-ALL relies on its GLS-i
activity32.
We report here our use of bioinformatics, genetic, and pharmacological approaches to investigate the metabolic features of
T-ALL. We identify OxPhos as a targetable dependence required
for mitochondrial energy production, whose disruption eliminates disease using preleukemic and leukemic cell lines, patient
samples, and patient-derived xenograft (PDX) models. We also
establish a mechanistic rationale for combining OxPhos-i and
GLS-i, by showing synergistic efﬁcacy of IACS-010759 and Lasparaginase-based chemotherapy against chemoresistant
NOTCH1-mutated T-ALL.
Results
Activity of OxPhos is linked to Notch1 status in murine preleukemic and human models of T-ALL. Bioinformatic analysis
of various datasets from T-ALL12,33, normal thymocytes34, and
murine T- ALL cell lines35 indicated that NOTCH1-bound target
genes (NBTs) were enriched for MYC targets, genes of the
OxPhos pathway, the tricarboxylic acid (TCA) cycle, and the
mitochondrial electron transport chain (ETC) (Fig. 1a)35,36,
possibly linking NOTCH1 signaling to MYC and OxPhos. During
normal thymocyte differentiation34, expression of NBTs increases
from the ETP stage onward, peaking at the DN3/DN4 stage, and
remains elevated up to the immature single positive (ISP) stage
(Fig. 1b). Beginning at the DN3 stage, there is a high expression
of NBTs that are involved in OxPhos, which sharply drop at the
DP stage (Fig. 1c), together with the global shutdown of canonical
NOTCH1 target genes. Moreover, following the introduction of
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the constitutively active NOTCH1 oncogene (Notch1/IC) into DP
cells37, gene set enrichment analysis (GSEA) showed upregulation
of NBTs exclusively within the OxPhos pathway, at both the
preleukemic (p < 0.0001) and leukemic (p < 0.0001) stages (Supplementary Fig. 1a, b).
Having established a possible link between NOTCH1 and
OxPhos in murine preleukemic T-cells, we next examined
whether NOTCH1 activation affects putative OxPhos activity in
human T-ALL, using RNA-seq data from two T-ALL clinical
trials12,33 and a data-driven network inference algorithm
(NetBID). As compared to samples without NOTCH1 mutation,
there was a higher activity of OxPhos signature genes in
NOTCH1-mutant T-ALL (p = 0.012) along with several pathways
associated with mitochondrial machinery (p = 0.01; Fig. 1d–f,
Supplementary Fig. 1c–e) and a lower activity of apoptosis
pathways (p = 0.0073; Fig. 1d, g; Supplementary Fig. 1c, f).
Furthermore, the comparison of dependence scores from
DepMap unbiased genome-scale CRISPR-Cas9 screening data38
between three T-cell lines (PF382, SUPT1, HSB2) to other
hematologic cell lines (N = 73) or other cancer cell lines
(N = 686) showed signiﬁcantly higher number of OxPhos genes
in T-ALL. In addition, OxPhos genes were signiﬁcantly overrepresented among T-ALL dependent genes, as compared to
those for hematologic malignancies or other cancer cell lines
(p = 0.03 and p = 0.048, respectively; Supplementary Fig. 1g)
suggesting the importance of OxPhos genes for T-ALL
survival38.Taken together, bioinformatic analysis provides evidence that oncogenic activation of NOTCH1 is associated with
OxPhos, and suggested that treatment with OxPhos-i could
reduce the viability of murine and human T-ALL, potentially
depending on NOTCH1 status.
OxPhos downstream of NOTCH1 is essential for preleukemic
and leukemic stem cell function. Our bioinformatic analysis
suggested that treatment with OxPhos-i could reduce the viability
of murine and human T-ALL, potentially depending on NOTCH1
status.
In the murine SCL-LMO1 transgenic model, progression to
acute leukemia is driven by the acquisition of Notch1 gain-offunction mutations, starting at 7–8 weeks of age (Fig. 2a;
Supplementary Fig. 2a), reproducing a major feature of the
human disease. Indeed, introducing the Notch1/IC oncogene that
drives elevated and activated NOTCH1 in thymocytes (Fig. 2b) is
sufﬁcient to transform SCL-LMO1-induced pre-LSCs into
hypercompetitive leukemia-propagating cells and to trigger
aggressive T-ALL without latency36,39. To directly address the
question whether NOTCH1 activation affects the response to
OxPhos-i, we harvested pre-LSCs at 1, 3, and 5 weeks of age, i.e.
at least one month before the appearance of Notch1 mutations
(Supplementary Fig. 2a). The functional importance of NOTCH1
activation was directly addressed by comparing cells expressing or
not the constitutively active Notch1/IC allele. When maintained
on stromal cells presenting the NOTCH1 ligand DL4 (MS5-DL4),
pre-LSCs from ﬁve genetic models: LMO1tg, SCLtgLMO1tg,
Notch1tg, LMO1tgNotch1tg, and SCLtgLMO1tgNotch1tg, showed
comparable growth inhibition upon OxPhos-i with IACS-010759,
and comparable IC50 in dose–response curves (Fig. 2c, d;
Supplementary Fig. 2b). Of note, the inhibitory effect of IACS010759 on pre-LSCs was observed when cells started to proliferate
in culture on day 2 and 3, but not on day 1 (Fig. 2e). In the
absence of DL4 stimulation, LMO1- or SCL-LMO1-induced preLSCs survived for 2 days without proliferation and were
insensitive to IACS-010759 (Fig. 2d, f). Under these conditions,
the Notch1 transgene was sufﬁcient to confer responsiveness to
IACS-010759, even though cell proliferation was minimal.
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Fig. 1 Oxidative phosphorylation downstream of NOTCH1 is essential for preleukemic stem cells function. a Gene set enrichment analysis of NOTCH1bound genes in Molecular Signatures Database. The list of genes in which NOTCH1 binding was observed within 2 kb of transcription start sites in murine
T-ALL cell lines was extracted as described in Materials and Methods. False discovery rates (FDRs) are shown for overlaps computed with Hallmark gene
sets or canonical pathways (Reactome and Kyoto Encyclopedia of Genes and Genomes). TCA: tricarboxylic acid; ETC, electron transport chain. b Dynamics
of NOTCH1 target gene expression during thymocyte differentiation. The numbers of NOTCH1 target genes that increased >1.3-fold at each transition (gray
bars, left axis). Gene expression data are from the Immunological Genome Project. GSEA was conducted on the gene sets whose expression increased at
each transitional stage. FDR values overlap with the OxPhos gene set (Hallmark) were computed as above (green bars, right axis). ETP, early T-lineage
precursor; DN3a, (CD4−CD8−CD25+CD44−CD28−), DN3b, (CD4−CD8−CD25+CD44−CD28+). c Heatmap of expression of NOTCH1-bound genes
within the OxPhos pathway. Ultralow input (ULI) RNA-seq data were obtained from IMMGEN. ETP, early thymocyte progenitor (LinlowCD25−CD44+Kit+),
DN2, double negative 2 (LinlowCD25+CD44+Kit+), DN3 (CD4−CD8−CD25+CD44−), DN4 (CD4−CD8−CD25−CD44−CD28+), ISP, immature single
positive (CD4−CD8+CD24hiTCRlo), DP (CD4+CD8+TCRloCD24hi), T4 (CD4+CD8− − TCRhi), T8 (CD4−CD8+TCRhi). d GSEA of the TARGET gene set
(Therapeutically Applicable Research to Generate Effective Treatments) (N = 265), indicated enrichment of genes related to glutamine metabolism,
mitochondrial metabolism as well as translation and downregulation of apoptosis-related genes in patients with NOTCH1-mutations (each vertical bar in xaxis is gene rank in the pathway list and y-axis represents running enrichment score). e The OxPhos gene signature in T-ALL patients from TARGET cohort.
f Enrichment of mitochondrial translation genes in T-ALL patients from TARGET cohort. g Enrichment of apoptosis-related genes in T-ALL patients from
the TARGET cohort; for (e), (f) and (g): two-sided t-test; The center line represents the median and whiskers represents maximum (Q3 + 1.5*IQR) and
minimum value (Q1+1.5*IQR).

Growth inhibition was not due to concurrent apoptosis in preLSCs nor decreased viability of the supporting stromal cells
(Supplementary Fig. 2c–f), indicating that OxPhox-i speciﬁcally
acts on pre-LSCs. Although cells expressing the Notch1/IC allele
were inhibited by IACS-010759, the curves did not reach the
same levels of maximum inhibition observed in DL4-stimulated

cultures (Fig. 2d, Supplementary Fig. 2b). We then compared
drug sensitivities by computing the areas under the curves
(AUC). As shown in Fig. 2g, drug sensitivity was highest in DL4stimulated cultures and all ﬁve genotypes cluster together. In the
absence of DL4 exposure, pre-LSCs separated into two clusters:
LMO1- and SCL-LMO1-induced pre-LSCs cluster with control
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cultures exposed to DMSO whereas all three Notch1/IC genotypes
cluster together, away from DMSO controls. Nonetheless, drug
sensitivity remained lower compared to DL4-stimulated cells.
Together with NOTCH1-occupancy of genes of the OxPhos
pathway35 (Fig. 1a), the response to OxPhos-i observed here
suggests two levels of drug sensitivity: one directly regulated via
NOTCH1 binding to OxPhos genes, and the other one associated
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with DL4-induced cell proliferation. Together, the genetic models
and the MS5-DL4 co-culture model establish a direct link
between NOTCH1 activation and OxPhos-i sensitivity.
Next, we asked whether NOTCH1 status impacts mitochondrial respiration in human models of T-ALL. Oxygen consumption rate (OCR) measurements in T-lymphocytes and T-ALL cell
lines separated by NOTCH1 mutation status showed an increased
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Fig. 2 NOTCH1 activation affects the response to OxPhos-inhibition of primary pre-LSCs. a Notch1 gene mutation in SCLtgLMO1tg preleukemic and
leukemic thymocytes. b Overexpression of NOTCH1 protein by ﬂow cytometry. Thymocytes from wt- and NOTCH1tg mice were stained with anti-NOTCH1
antibody or an isotype control. c dose–response of primary pre-LSCs to IACS-010759, co-cultured on MS5-DL4 stromal cells followed by 48 h drug
treatment (mean ± SD, n = 3 independent experiments in triplicates). d Dose–response of pre-LSCs to IACS-010759 treatment, co-cultured on
MS5 stromal cells followed by 48 h drug treatment (mean ± SD, n = 3.independent experiments in triplicates). e Effects of IACS-010759 treatment
(133 nM or DMSO) on viability of pre-LSCs cultured on MS5-DL4 (mean ± SD, n = 3 independent experiments). f Effects of IACS-010759 treatment
(133 nM or DMSO) on viability of pre-LSCs cultured on MS5 (mean ± SD, n = 3 independent experiments). g Pre-LSC sensitivity to IACS-010759 for the
indicated genotypes. The Area under the curves (AUC) were computed from dose–response data illustrated in (c). Shown is the AUC difference obtained
between DMSO (black ring) and drug-treated cells (p < 0.00001, multiple unpaired t tests, n = 3 mice per genotype, in triplicates); with (green) and
without DL4 (blue), in pre-LSCs with or without NOTCH1 oncogene in the absence of DL4. h Basal oxygen consumption rate (OCR) in T-lymphocytes
(n = 7), NOTCH1-wt (n = 3) and -mutant cell lines (n = 7) by Mito Stress Test assay (mean ± SD, n = 3 independent measurements for each line, 4
replicates); one-way ANOVA; *p < 0.05; ***p < 0.001. i IC50 for basal OCR inhibition (Supplementary Figs. 3c and 4) for T-lymphocytes (n = 4) and
NOTCH1-wt (n = 3) and -mutated T-ALL cell lines (n = 7) (mean ± SD, n = 3 independent experiments for each line, 4 replicates); one-way ANOVA;
*p < 0.05; ***p < 0.001. j IC50 for viability inhibition for T-lymphocytes (n = 5), NOTCH1-wt (n = 3) and -mutant cell lines (n = 7) treated with IACS-010759
(0–123 nM, 96 h); (mean ± SD, n = 3 independent experiments); one-way ANOVA; ns-no signiﬁcance, **p < 0.005. k Viable cell number in T-lymphocytes
(n = 7), NOTCH1-wt (n = 3) and -mutant (n = 7) T-ALL cell lines, treated with IACS-010759 (1, 10, 100 nM, 96 h), (mean ± SD, n = 3 independent
experiments per line, 3 replicates); two-way ANOVA: ns-no signiﬁcance, *p < 0.05; **p < 0.005; ***p < 0.001; and ****p < 0.0001. l ROS (MFI) treated with
IACS-010759 (1, 10, 100 nM; 96 h) in T-lymphocytes (n = 6), T-ALL cell lines with wt- (n = 3) and mutant NOTCH1 (n = 7); (mean ± SD, n = 3 independent
experiments per line, 3 replicates); two-way ANOVA: ns-no signiﬁcance, *p < 0.05; **p < 0.005; ***p < 0.001; and ****p < 0.0001.

OCR in a subset of cells with NOTCH1 wild type (wt) (p = 0.03;
Fig. 2h) and in all cell lines harboring NOTCH1 mutation
(p = 0.0004; Fig. 2h) compared with OCR of healthy
T-lymphocytes. Albeit the NOTCH-mutant cells on average
showed higher basal and maximal OCR (Supplementary Fig. 3a),
these differences did not reach statistical signiﬁcance. All T-ALL
cell lines showed high expression of mitochondrial complexes
I–V, with no clear correlation between mitochondrial protein
assembly level and NOTCH1 status (Supplementary Fig. 3b).
As expected, IACS-010759 inhibited OxPhos across T-ALL cell
lines (n = 11), reducing basal and maximal OCR in both
NOTCH1-wt and -mutant cell lines (p = 0.05 and p = 0.005,
respectively, Supplementary Figs. 3c–d, 4), with the latter showing
greater sensitivity to OCR inhibition when compared to
T-lymphocytes (p = 0.0006, Fig. 2i, Supplementary Fig. 3e).
Consistent with this, IACS-010759 produced striking dosedependent inhibition of ATP production in T-ALL lines
(Supplementary Fig. 3f), with the lowest IC50 in NOTCH1mutant lines versus T-lymphocytes (p = 0.0006, Fig. 2j), while
only moderate ATP and viability reduction of less than 20% at the
highest dose was seen in healthy T-lymphocytes (Supplementary
Fig. 3f–h). The response to IACS-010759 observed in matured
T-lymphocytes was not increased by stimulation with DLL4.
Neither ATP production, cell number, nor apoptosis rate were
signiﬁcantly changed upon combined DLL4 stimulation and
IACS-010759 treatment (Supplementary Fig. 3i–k). Reduced ATP
production upon OxPhos-i was paralleled by decreased viability
in T-ALL cell lines, PDX models and primary T-ALL samples
(Supplementary Fig. 3g, h). At the clinically achievable concentration of 10 nM, IACS-010759 reduced viability substantially in
both NOTCH1-wt (p = 0.01) and NOTCH1-mutated cells
(p < 0.0001, Fig. 2k), and minimally affected the viability of
healthy T-lymphocytes (Fig. 2k). Similar effects were seen at
100 nM dose of IACS-010759, producing signiﬁcant reduction in
both NOTCH1-wt (p = 0.0093) and mutants (p < 0.0001, Fig. 2k).
These results correlated with basal OCR changes (Supplementary
Fig. 5a, R2 = 0.4572, p = 0.0079). Of note, IACS-010759 increased
signiﬁcantly the level of reactive oxygen species (ROS), where
NOTCH1-mutation contributed to 8-fold higher and NOTCH1wt 2-fold higher ROS increase when compared to T-lymphocytes
(p = 0.0012), leading to higher ROS accumulation at 10 nM and
100 nM doses (p = 0.05 and 0.0036) and indicating a distinct
propensity to undergo redox imbalance upon OxPhos-i (Fig. 2l).
ROS increase correlated with viability reduction (R2 = 0.559,

p = 0.0021), indicating that T-ALL cells have ineffective mechanisms of coping with oxidative stress (Supplementary Fig. 5b).
DLL4 incubation did not produce signiﬁcant changes in
respiration of matured T-lymphocytes (Supplementary Fig. 5c±f),
suggesting that DLL4 stimulation of NOTCH1 plays a role mainly
at the early stages of lymphocyte development.
OxPhos-i in NOTCH1-mutated cells also produced timedependent changes in total levels and phosphorylation status of
multiple metabolism-relevant proteins (Supplementary Fig. 5g),
including activation of mTOR and glycolytic enzymes, activation
of LKB1 and AMPK in response to ATP depletion, and
upregulation of DNA damage (pH2AX) in response to energetic
stress and ROS accumulation. GSEA of OxPhos-i-induced
transcriptional changes revealed downregulation of mitochondrial gene sets involving transcriptional processes, the ETC, and
cytochrome c release (p = 0.046; Supplementary Fig. 5h).
In summary, our data provide direct evidence that liganddependent activation of NOTCH1 signaling by DLL4 or by the
NOTCH1 oncogene upregulates the OxPhos pathway and confers
responsiveness of primary pre-LSCs and human T-ALL cells to
OxPhos-i.
OxPhos-I induces distinct metabolic reprogramming in
NOTCH1-mutated T-ALL toward reductive metabolism of
glutamine. To investigate further the role of NOTCH1 in regulating metabolism in T-ALL cells, we analyzed the impact on
cellular processes of supplementation or withdrawal of essential
nutrients glutamine (Gln), glucose (Glc), and pyruvate (Pyr).
Supplementation with Gln alone, but not with Glc, contributed
to 50% of ATP generation by NOTCH1-mutant cell lines
(p = 0.0064; Fig. 3a, Supplementary Fig. 6a). The addition of Pyr
with Gln further improved ATP generation to 80% (p = 0.001)
and increased basal and maximal OCR to the level observed in
complete medium (Gln + Glc+Pyr; p = 0.001; Fig. 3b, Supplementary Fig. 6b), but had no impact on extracellular acidiﬁcation
rates (ECAR).
The presence of Gln and Pyr without Glc in NOTCH1-mutant
cells contributed to a distinct aerobic metabolic phenotype with
predominant OxPhos activity, as indicated by the basal OCR/
ECAR ratio, while the addition of Glc clustered the metabolic
proﬁle toward an energetic/glycolytic phenotype (Fig. 3c). In
contrast, NOTCH1-wt cells showed their most efﬁcient ATP
production and growth under Glc supplementation (p = 0.001;
Supplementary Fig. 6c). These observations revealed divergent
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nutrient utilization, with NOTCH1-wt cells relying strongly on
Glc, while NOTCH1-mutants were dependent on Gln to activate
OxPhos and generate ATP.
To investigate whether T-ALL cells switch to glycolysis to cope
with OxPhos-i, we measured the effects of IACS-010759 on basal
and maximal ECAR, in the presence of Gln, before and after Glc
supplementation (Fig. 3d; Supplementary Fig. 7a, b). With Gln
6

only, both NOTCH1-wt and -mutant relied only on OxPhos (high
OCR, low ECAR) (Fig. 3e, f), and IACS-010759 inhibited Glndriven OCR in a dose-dependent manner (Supplementary Fig. 7).
Acute Glc addition produced an immediate shift toward maximal
glycolytic activity (p = 0.005, Fig. 3e, f), however this switch
toward glycolysis was signiﬁcantly higher for NOTCH1-wt than
in mutant, thereby establishing a new metabolic equilibrium
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Fig. 3 Mitochondrial complex I inhibition induces distinct metabolic reprogramming followed by reductive metabolism of glutamine in NOTCH1mutated cell lines, uncovering a potential metabolic mechanism of acquired resistance under OxPhos blockade. a ATP levels for NOTCH1-mutated
T-ALL (n = 4) treated 96 h in media with: no nutrients, pyruvate (Pyr), glutamine (Gln), glucose (Glc), Gln+Pyr, Glc+Pyr, Glc+Gln, Glc+Pyr+Gln,
(mean ± SD, n = 4 independent experiments, 3 replicates); one-way ANOVA: *p < 0.05; **p < 0.005; ***p < 0.001; ****p < 0.0001. b Basal OCR of 4
NOTCH1-mutated T-ALL cell lines treated 24 h as in (a), (mean ± SD, n = 3 independent experiments, 4 replicates); one-way ANOVA: *p < 0.05;
**p < 0.005; ***p < 0.001; ****p < 0.0001. c Metabolic phenotype (basal OCR/basal ECAR ratio) as in (a); (mean ± SD, n = 3 independent experiments, 4
replicates). d Extracellular acidiﬁcation rate (ECAR) in NOTCH1-mutated T-ALL cell line PF-382 after IACS-010759 treatment (0–123 nM, 4 h); Glycolysis
Stress Test (mean ± SD, n = 3 independent experiments, 4 replicates). e Basal ECAR of NOTCH1-wt (n = 3) and -mutated (n = 6) cell lines treated 24 h in
media with Gln only (blue) and after acute injection of Glc (black); (Glycolysis Stress Test), (mean ± SD, n = 3 independent experiments, 4 replicates);
two-way ANOVA: ***p = 0.0002. f Basal OCR in NOTCH1-wt (n = 3) and -mutated (n = 6) cell lines treated as in (e); (mean ± SD, n = 3 independent
experiments, 4 replicates); two-way ANOVA: *p = 0.0250. g Basal ECAR of NOTCH1-mutated (n = 5) and -wt (n = 3) cell lines treated with IACS-010759
(0–123 nM, 4 h); (mean ± SD, n = 3 independent experiments, 4 replicates); two-tailed t test: ****p < 0.0001. h Glycolytic capacity in NOTCH1-mutated
(n = 5) and -wt (n = 3) cell lines treated with IACS-010759 (0–123 nM, 4 h), Glycolysis Stress Test; (mean ± SD, n = 3 independent experiments, 4
replicates); one-way ANOVA: ****p < 0.0001. i ATP production (%) for NOTCH1-mutant (n = 8) and -wt (n = 3) cell lines treated with IACS-010759
(0–123 nM, 4 h), ATP Rate Assay; (mean ± SD, n = 3 independent experiments, 4 replicates); one-way ANOVA: ****p < 0.0001. j Levels of citrate and αketoglutarate and citrate/α-ketoglutarate ratio over time in NOTCH1-mutated cell line PF382; (mean ± SD, n = 1, 4 replicates); two-way ANOVA:
****p < 0.0001. k Stable isotope-resolved metabolomics ultra-high-pressure liquid chromatography MS analysis (SIRM) of NOTCH1-mutant PF-382 cell line
cultured with 13C5,15N2-glutamine, treated with DMSO or IACS-010759 (10 nM, 12 h); (mean ± SD, n = 1, 4 replicates). two-tailed t-test; *p < 0.05;
**p < 0.005; ***p < 0.001; and ****p < 0.0001.

(high OCR, high ECAR) (Fig. 3e, f). This was accompanied by
signiﬁcant decrease of OCR observed upon Glc injection,
indicating switch toward glycolysis with reduced OxPhos
utilization in NOTCH1-mutants and thus more tightly regulated
nutrient utilization. Furthermore, independently of OxPhos
activity, NOTCH1-wt cell lines displayed higher glycolysis
(p = 0.0001, Fig. 3g) and glycolytic capacity, showing nearly
3-fold higher ECAR than NOTCH1-mutants at both baseline and
upon OxPhos-i (p = 0.0001, Fig. 3h).
The simultaneous real-time measurement of ATP (Seahorse)
generated by glycolysis and OxPhos, in the presence of both Gln
and Glc, showed a comparable inhibition of OxPhos-derived ATP
by IACS-010759 in all cell lines. However, glycolysis-derived ATP
generation was lower in NOTCH1 mutants (p < 0.0001; Fig. 3i;
Supplementary Fig. 8a, b), conﬁrming the distinct role of
NOTCH1-status in the maintenance of metabolic equilibrium
upon OxPhos-i.
IACS-010759, like other Complex I inhibitors, has been shown
to impair mitochondria by blocking the TCA cycle (thereby
reducing concentrations of its metabolites: citrate, α-ketoglutarate
[α-KG], succinate, fumarate, and malate) and by inhibiting ATP
production and decreasing aspartate levels (thereby depleting
energy and blocking nucleotide biosynthesis)17,19,21,25,40. To
deﬁne the metabolic effects of OxPhos-i in NOTCH1-mutated
T-ALL cells, we performed an untargeted metabolomics analysis
that showed accumulation of nucleoside monophosphate (NMP)
(p = 0.04) and redox imbalance, as indicated by diminished ratios
(reductive to oxidized) of glutathione and coenzyme Q10
(CoQ10) (Supplementary Fig. 9a). Also, OxPhos-i at 10 nM
decreased levels of citrate, succinate, L-glutamine, and L-aspartate,
slightly increased fumarate and malate, and transiently increased
α-KG (p < 0.0001; Supplementary Fig. 9b, c). Since the elevated αKG/citrate ratio indicates utilization of reductive OxPhos41,42, we
next analyzed the dynamics of α-KG/citrate ratio changes upon
OxPhos-i. Indeed, a spike in the α-KG/citrate ratio was observed
after 12 h (p < 0.0001; Fig. 3j; Supplementary Fig. 9c), indicating a
switch to reductive OxPhos metabolism upon OxPhos blockade.
To further support reductive oxidative phosphorylation as a
mechanism of counteracting OxPhos blockade, we next performed stable isotope-resolved metabolomics (SIRM) to follow
the fate of incorporation of isotopically-enriched 13C5,15N2glutamine (13C5,15N2-Gln) or 13C6-glucose (13C6-Glc) in
NOTCH1-mutant (Fig. 3k; Supplementary Fig. 10) and
NOTCH1-wt cell lines (Supplementary Fig. 11a, b). As expected,

OxPhos-i decreased levels of TCA intermediates in NOTCH1mutant cells (Fig. 3k). We also observed simultaneous incorporation of Glc and its utilization in glycolysis, indicated by a
moderately increased rate of lactate enrichment (Supplementary
Fig. 10, 11a). Furthermore, the increase of 13C515N2-Gln
isotopomer fractions (M+5 citrate, M+4 malate, and M+4
fumarate) indicated an enrichment of Gln incorporation (Fig. 3k),
supporting a compensatory Gln inﬂux into the TCA cycle upon
OxPhos blockade.
Taken together, these results demonstrate an increase in Gln
oxidative phosphorylation in NOTCH1-mutated cell lines and
selective boosting to utilize Gln in the reductive oxidative
phosphorylation pathway upon OxPhos-i, offering a possible
mechanism of metabolic escape in NOTCH1-mutated T-ALL.
Blocking the glutamine pathway is lethal to NOTCH1-mutant
T-ALL cells when combined with complex I inhibition. Because
reductive metabolism of Gln was increased by OxPhos-i, we
examined further the importance of Gln metabolism in T-ALL.
GSEA of TARGET T-ALL RNA-seq datasets showed that genes
involved in Gln metabolism are expressed more highly by
NOTCH1-mutant tumors (p = 0.0067; Fig. 4a). These observations prompted the hypothesis that the dual inhibition of both
OxPhos and Gln metabolism would facilitate the efﬁcacy of
OxPhos-i against T-ALL. We tested this hypothesis by determining the sensitivity to IACS-010759 of cell lines and primary
T-ALL samples, under varying conditions of selective supplementation of essential substrates (Gln, Glc, and Pyr). NOTCH1mutant cell lines showed higher sensitivity to IACS-010759 in the
presence of Gln (blue curve) and glutamine+pyruvate (orange
curve), with average IC50s of 0.677 nM and 0.552 nM (p < 0.05
and p < 0.0005 respectively, Fig. 4b-c; Supplementary Fig. 12a–c).
These results indicate that Gln and Pyr, in the absence of Glc,
support OxPhos and sensitize NOTCH1-mutated T-ALL cells to
OxPhos-i. In contrast, Gln+Pyr supplementation reduced the
sensitivity to OxPhos-i of NOTCH1-wt cells (Supplementary
Fig. 12a, b). In NOTCH1-mutated T-ALL, the growth-inhibitory
effect of OxPhos-i in Gln/Pyr-supplemented medium was
reduced by the addition of Glc (black curve) (Fig. 4b, c;
Supplementary Fig. 12a–c). Exposure to Glc, alone or in the
presence of Gln, switched NOTCH1-mutated cells from OxPhos
towards glycolysis (brown curve), ﬂattening the dose–response
curve upon OxPhos-i, indicating reduced sensitivity to IACS010759; however, this increased the sensitivity of NOTCH1-wt cells
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to OxPhos-i (p < 0.0001; Fig. 4b, c; Supplementary Fig. 12a–c).
These results suggest that the maintenance of OxPhos function
depends on Gln in NOTCH1-mutated cells and that Gln is crucial
for the sensitivity to OxPhos-i (p = 0.0001, Fig. 4c; Supplementary
Fig. 12a, b).
We next reassessed the impact of OxPhos-i on T-ALL cells in
the context of inhibiting GLS, a key enzyme in Gln utilization.
8

Compared to treatment with IACS-010759 alone, GLS knockdown combined with OxPhos-i inhibited cell growth, reduced
cell viability (Supplementary Fig. 13a), reduced basal and
maximal OCR (Fig. 4d; Supplementary Fig. 13b), and resulted
in inhibition of the c-MYC, Akt/mTOR, and AMPK pathways,
initiation of the DNA damage response pathway (γ-H2AX), and
activation of the apoptosis pathway (cleaved PARP and cleaved
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Fig. 4 Blockade of glutamine pathway through glutaminase knockdown and glutaminase inhibition in combination with complex I inhibition induces
metabolic shutdown in T-ALL cells in vitro. a Enrichment of glutamine metabolism components in T-ALL TARGET cohort; (Gene Ontology analysis); twosided t test; The center line represents the median and whiskers represents maximum (Q3+1.5*IQR) and minimum value (Q1+1.5*IQR). b Viability of
NOTCH1-mutated T-ALL cell lines (96 h, 0–100 nM of IACS01759) upon following conditions: no nutrients, pyruvate (Pyr), glutamine (Gln), glutamine
+pyruvate (Glut+Pyr), glucose+pyruvate (Glc+Pyr), glucose+glutamine+pyruvate (Glc+Glut+Pyr), normalized to DMSO. c AUC upon IACS-010759
treatment (by CTG) calculated from (b), normalized to DMSO from Gln+Glc+Pyr, for NOTCH1-wt (blue) (n = 3) and NOTCH1-mutated (black) T-ALL cell
lines (n = 4) (mean ± SD, n = 3 independent experiments, n = 3 replicates/condition). Two-way ANOVA; *p = 0.02; ***p = 0.0002; ****p < 0.0001;
d Representative OCR response in NOTCH1-mutated T-ALL cell lines JURKAT subjected to doxycycline-induced knockdown of GLS (blue) and treatment
with IACS-010759 (10 nM) for 4 h (red), or the combination (green) (mean ± SD, n = 3 biological replicates, n = 4 replicates/condition). e Cell viability in
NOTCH1-mutated T-ALL patient samples (n = 4) treated with CB-839 (1 μM) and IACS-01759 (10 nM) after 96 h, by FL (mean ± SD, n = 4 independent
patient samples, n = 3 replicates/condition); one-way ANOVA; *p = 0.039; **p = 0.0017; ****p < 0.0001. f Reactive oxygen species (ROS) -MFI of in
NOTCH1-mutant T-ALL cell lines (n = 3) treated 96 h with CB-839 (1 μM) and IACS-010759 (10 nM). (mean ± SD, n = 3) by FL; one-way ANOVA; *p =
0.0202; ***p = 0.0005; ****p < 0.0001. g Basal OCR in NOTCH1-mutated T-ALL cell lines after treatment with vehicle, IACS-010759 (10 nM, 4 h), CB-839
(1 μM, 12 h), or IACS-010759/CB-839 combination (mean ± SD, n = 7 cell lines, n = 3 independent experiments, n = 4 replicates per condition); one-way
ANOVA: ***p = 0.0003; ****p < 0.0001. h SIRM ultra-HPLC MS of NOTCH1-mutated T-ALL cell line PF-382 after enrichment with 13C515N2-glutamine and
treatment with the combination of 10 nM IACS-010759 and 1 μM CB-839 or vehicle for 12 h. i Gene expression analysis in NOTCH1-mutant T-ALL after
treatment with the combination of 10 nM IACS-010759 and 1 μM CB-839 compared to vehicle; (x-gene rank in the pathway list; y-running enrichment
score).

caspase-3) (Supplementary Fig. 13c). Furthermore, treatment
with the GLS-i CB-839 in combination with OxPhos-i led to a
synergistic drop in cell viability (Supplementary Fig. 14a),
reﬂected by an AUC decrease (p = 0.001; Supplementary Fig. 14b)
and by delta BLISS index values (Supplementary Fig. 14c). The
efﬁcacy of dual inhibition was conﬁrmed across cell lines
(Supplementary Fig. 14d, e) and primary NOTCH1-mutated
T-ALL blasts (p < 0.0001, Fig. 4e), by decreased cell number and
increased apoptosis rate for the GLS-i/OxPhos-i combination.
Supplementation with Pyr and Gln failed to reverse the
inhibitory effects of dual inhibition (Supplementary Fig. 14f).
Given that Gln contributes to the redox homeostasis, we tested
the impact of the dual blockade on ROS induction and showed
that GLS-i plus OxPhos-i elevated ROS greater than OxPhos-i
alone (p < 0.0001; Fig. 4f). Finally, the GLS-i/OxPhos-i combination additively reduced basal and maximal OCR, but only in
NOTCH1-mutant cells (p < 0.0001; Fig. 4g; Supplementary
Figs. 15a, b, 16a, b). Of note, dual GLS-i/OxPhos-i blockade
only moderately reduced the cellular respiration (24 h) and ATP
levels (72 h) of healthy bone marrow cells (Supplementary
Fig. 16c, d) and did not signiﬁcantly affect colony formation
(Supplementary Fig. 16e, f).
The evidence of successful blockade of glutaminolysis by
GLS-i upon OxPhos-i was conﬁrmed by SIRM in both
NOTCH1-mutated (Fig. 4h; Supplementary Figs. 17, 19a) and
NOTCH1-wt cell lines (Supplementary Fig. 18a, b, 19b). GLS-i/
OxPhos-i severely reduced the levels of TCA cycle intermediates
citrate, α-KG, and succinate (p < 0.0001), and decreased the
levels of fumarate (p = 0.012), malate (p = 0.0003), aspartate
(p < 0.0001), and glutamate (p < 0.0001), accompanied by
relative accumulation of Gln (Fig. 4h, Supplementary Figs. 17,
18a, b, 19a, b). These results demonstrate a very slow TCA
turnover indicative of cellular exhaustion (Fig. 4h; Supplementary Fig. 17). Similar effects were observed for NOTCH1-wt
cells, without signiﬁcant accumulation of Gln in the labeled
fraction (Supplementary Fig. 18a, b). This potent metabolic
shutdown was reﬂected by GSEA, indicating the downregulation of genes involved in the TCA cycle, ETC, ATP response
(Fig. 4i; Supplementary Fig. 20a, b), and mitochondrial activity
(Supplementary Fig. 20a), accompanied by an upregulation of
apoptosis activation in response to DNA damage and catabolic
processes (Fig. 4i; Supplementary Fig. 20a, b). Given that redox
balance is controlled by glutathione concentration43,44, we
tested whether N-acetylcysteine (NAC) supplementation would
rescue the effects of OxPhos-i alone or combined with GLS-i on

viability, apoptosis, and ROS production. Surprisingly, cotreatment with NAC at 0.5 or 2.0 mM45 increased the
cytotoxicity of IACS-010759 or IACS-010759/CB-839 combination in T-ALL cells, decreasing cell number, inducing apoptosis,
and triggering a stronger accumulation of ROS. These data
suggest that NAC supplementation is unable to quench the ROS
accumulation and glutathione depletion upon OxPhos-i/GLS-i
treatment, making those changes irreversible. On the contrary,
NAC completely rescued the growth-inhibitory effects of CB839 alone (Supplementary Fig. 21a–c).
Together, these data demonstrate that dual OxPhos and
glutamine pathway blockade induced profound metabolic shutdown in T-ALL cells with NOTCH1 mutations, in turn resulting
in apoptosis.
Blockade of glutamine metabolism with complex I inhibition
improves depth of tumor burden reduction in vivo. We evaluated dual OxPhos/GLS inhibition in vivo, using a Notch1mutated GLSﬂ/ﬂ murine T-ALL model29 in C57BL/6 mice
(Fig. 5a). Following established leukemia engraftment in peripheral blood at day 7 (Supplementary Fig. 22a, b), mice received
vehicle or IACS-010759 therapy, alone or with concomitant
tamoxifen administration to induce GLS knockout selectively in
leukemic cells. After only 5 days of dual pharmacologic/genetic
blockade, disease burden was reduced in both peripheral blood
(PB) (Fig. 5b) and bone marrow (BM) (p = 0.0001; Fig. 5c and f),
with substantial clearance of leukemia cells in the spleen
(p = 0.013; Fig. 5d), reduction of splenomegaly (Fig. 5e) and
clearance of leukemia cells in the liver (Fig. 5f). Consistent with
in vitro observations, metabolomic analysis of PB from leukemic
mice subjected to dual intervention, revealed an accumulation of
NMP, with decreased ATP and TCA intermediates, indicative of
profound metabolic reprogramming that suppressed all critical
amino acid and nucleotide biosynthesis pathways (Ingenuity
Pathway Analysis, IPA) (Fig. 5g, Supplementary Fig. 22a, b). The
long-term evaluation found that leukemia progression was signiﬁcantly delayed in mice treated with either IACS-01075 or
subjected to GLS knockout (p = 0.0001; Fig. 5h). This antileukemic effect was signiﬁcantly enhanced under dual inhibition
(p < 0.0001; Fig. 5h), with no circulating leukemia cells in peripheral blood up to day 220 (Fig. 5i). Taken together, our results
demonstrate that blocking GLS in combination with complex I
inhibition provides a powerful approach to abrogate leukemia
progression in vivo.
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combined with OxPhos-i. Dexamethasone and vincristine
increased OCR signiﬁcantly (p = 0.0001; Supplementary Fig. 23a)
and led to moderate reductions of cell viability (Supplementary
Fig. 23b, c). L-asparaginase similarly induced OCR (p = 0.0001;
Supplementary Fig. 23a) but decreased viability potently as
monotherapy (Supplementary Fig. 23d). When combined with
OxPhos-i, all drugs synergized to reduce viability, with the most
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Fig. 5 Complex I inhibition in combination with glutaminase deletion impedes Notch1-mutant T-ALL leukemia development, improves tumor burden
reduction, and extends overall survival in a murine model. a Schematic of study design utilizing murine Notch1-mutated GLS ﬂ/ﬂ. b GFP+mCD45+
leukemia cells (%) in PB from mice bearing murine Notch1-mutated GLS ﬂ/ﬂ T-ALL cells after 5 days of treatment as shown in (a) (mean ± SD, n = 3
individual mice per treatment arm); one-way ANOVA; **p = 0.0025. c GFP+mCD45+ leukemia cells (%) in BM from mice as in (b) (mean ± SD, n = 3
individual mice per treatment arm); one-way ANOVA, **p = 0.001; and ***p = 0.0005. d GFP+mCD45+ leukemia cells (%) in spleens from mice as in
(b) (mean ± SD, n = 3 individual mice per treatment arm); one-way ANOVA, *p = 0.013. e Spleens harvested from mice bearing murine Notch1-mutated
GLS ﬂ/ﬂ T-ALL cells following 5 days of treatment with vehicle; IACS-010759; tamoxifen; or combination of IACS-010759 and tamoxifen (n = 3). f H&E
staining of BM, spleen and liver from one representative mouse from each group, selected based on complementary FL results from (c) and (d). Scale bars
represent 100 μm; from the same experiment as FL data. g Heatmap of MS analysis of metabolites in PB of mice bearing murine Notch1-mutated GLS ﬂ/ﬂ
T-ALL cells after 5 days of treatment with vehicle; IACS-010759; tamoxifen; or IACS-010759 and tamoxifen; (mean log of fold-change ratio over the level
of metabolites measured in mice treated with vehicle); (mean ± SD, n = 4 individual mice/group). h Kaplan–Meier survival curves of mice transplanted with
murine Notch1-mutated GLS ﬂ/ﬂ T-ALL. Mice (n = 5 per treatment arm) were treated with vehicle; tamoxifen (1 mg/mouse over 5 days); IACS-010759
(5 days per week 5 mg/kg Mo–Fr) or concomitantly with IACS-010759 and tamoxifen; treatment was initiated after detection of GFP+ cells in PB by FL at
day 7; log-rank test, ***p < 0.005, ****p < 0.0001. i Weekly tumor burden monitoring by detection of GFP+mCD45+ leukemia cells in PB in mice as
indicated in (h); the timeframe of treatment is labeled by the yellow windows on the graph; (mean ± SD, n = 5 individual mice per treatment arm).

potent effect observed in the VXL combination (Supplementary
Fig. 23e). Further, in comparison to OxPhos-i or VXL alone, the
VXL/OxPhos-i combination potently reduced both basal and
maximal OCR only in NOTCH1 mutants (p < 0.0001; Supplementary Figs. 24a, b; 25a, b). In contrast, the impact of basal and
maximal OCR and ECAR in healthy bone marrow cells was
moderate after pre-treatment with OxPhos-i/VXL for 24 h
(Supplementary Fig. 25c), did not signiﬁcantly impact ATP
production after 72 h (Supplementary Fig. 25d) and did not affect
the colony-forming capacity (Supplementary Fig. 25e).
VXL/OxPhos-i, like GLS-i/OxPhos-i, led to metabolic shutdown as measured by SIRM (Supplementary Figs. 26a, b, 27a, b),
with expected changes in TCA metabolites citrate, α-KG,
succinate (p < 0.0001) and moderate changes in malate (Supplementary Fig. 28a, b). The L-Asparagine driven glutaminedepleting effects were observed in media obtained after incubating cells with VXL and VXL/OxPhos-i, with a reduction of
glutamine level down to 70% of control for NOTCH1-mutated
cells (p = 0.0004, Supplementary Fig. 26c) and NOTCH1-wt cells
(p = 0.02, Supplementary Fig. 27c), respectively. Further, complete depletion of asparagine (p < 0.0001), accumulation of
glutamate (p < 0.0001) and aspartate (p < 0.0001) were observed
in media with VXL treatment (Supplementary Figs. 26c, 27c).
This translated into intracellular depletion of Asparagine
(p < 0.0001) and decrease in Aspartate level in VXL/OxPhos-i
treated cells (p = 0.0003; Supplementary Fig. 28a, b).
Similar to results obtained for CB-839, we observed rescue after
treatment of JURKAT and PF382 cells with NAC of 2 mM only in
VXL treatment; in conditions containing OxPhos-i, NAC
treatment led to deeper reduction of viable cell number
(p < 0.0001), increased apoptosis rate (p < 0.0001) and enhanced
ROS accumulation (p < 0.0001) (Supplementary Fig. 29a–c).
Next, we investigated the effect of VXL/OxPhos-i on the
metabolic and transcriptomic proﬁles of T-ALL PDXs with
advanced disease. The pharmacodynamic proﬁle of mice bearing
70-80% of leukemia cells in PB was determined after 12 h of
treatment with IACS-010759, VXL, or VXL/IACS-010759.
Metabolome analysis revealed profound downregulation of
pathways related to OxPhos in cells derived from PB, spleen,
and BM after OxPhos-i (Fig. 6a; Supplementary Figs. 29d, 30, 31),
facilitated further by VXL. Leukemia cells from PB, BM, and
spleen displayed a striking reduction in citric acid, isocitric acid,
α-KG, succinate, fumarate, and malate, as well as lesser decreases
in aspartate and Gln after VXL/OxPhos-i combination therapy
(Fig. 6a; Supplementary Figs. 29d, 30, 31). These results indicate
effective blockade of glutaminolysis and induction of redox
imbalance, evidenced by low levels of glutathione and homocysteine. VXL/OxPhos-i reduced nucleotide triphosphates (NTP),

leading to blockade of DNA and RNA synthesis (Fig. 6a;
Supplementary Figs. 29d, 30, 31). Pathway analysis by IPA
conﬁrmed that VXL/OxPhos-i upregulated AMPK and downregulated the sirtuin pathway, CoQ10 biosynthesis, and nucleotide biosynthesis (Supplementary Fig. 29e), as reﬂected further by
OCR reduction (p < 0.0001; Supplementary Fig. 32a) and downregulated pathways showed by GSEA (Supplementary Fig. 32b).
The impact of these metabolic changes was further validated by
single-cell CyTOF analysis, which conﬁrmed the reduction in PB
leukemia cells by only 12 h of treatment in vivo. Fractions of
T-ALL cells expressing CD45, CD7, and CD3 were reduced and
showed reduced expression of Ki67 and other intracellular
markers such as NOTCH1, p-p38, c-MYC, p-ERK, and
p-H2AX (Fig. 6b, c). GSEA of global gene expression changes
occurring in vivo after VXL/OxPhos-i showed a global shutdown
of all mitochondria-related processes, indicating that this
treatment negatively impacted a wide spectrum of metabolic
and cellular processes in leukemia cells (Fig. 6d; Supplementary
Fig. 32b).
Finally, we determined the short-term (5 days) and long-term
effects of VXL/OxPhos-i on disease progression and survival in
mice bearing human T-ALL (Supplementary Fig. 33a). In all three
NOTCH1-mutated T-ALL PDX models, OxPhos-i/VXL produced
a profound reduction of spleen size (Supplementary Fig. 33b),
spleen weight (p < 0.0001; Supplementary Fig. 33c), and tumor
burden reduction in PB (Supplementary Fig. 33d), spleen (Fig. 6e;
Supplementary Fig. 33f), and BM (Supplementary Fig. 33e, f).
Disease progression, as measured by circulating leukemia burden,
was 2–3-fold slower with VXL/OxPhos-i (Fig. 6f), translating into
longer overall survival in the VXL/OxPhos-i mice cohort
(p < 0.0001; Fig. 6g). Taken together, our data indicate that
OxPhos-i combined with standard-of-care chemotherapy containing L-asparaginase, with its GLS-inhibitory activity, effectively
induces metabolic and transcriptomic cellular catastrophe that
impedes leukemia progression and leads to the extension of
survival.
Discussion
Our study characterized the metabolic features of NOTCH1mutated and NOTCH-wt T-ALL and elucidated the link between
NOTCH1 and mitochondrial activation. Our ﬁndings suggest that
targeting OxPhos in T-ALL is an effective way to control disease
burden in vivo and that compensatory metabolic mechanisms
upon OxPhos-i can be overcome by inhibiting reductive metabolism of the glutamine pathway.
OxPhos is a well-studied target in malignancies, with upregulated OxPhos activity being observed in AML and other hematologic and solid tumors. IACS-010759, a potent small molecule
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with selective inhibitory effects on OxPhos, has been studied in
these indications20,21,28,46.
We previously showed that T-pre-LSCs are more resistant to
mainstay chemotherapy agents than the bulk of leukemic cells47.
We now provide direct evidence that pre-LSCs in a T-ALL
murine model are sensitive to OxPhos-i by IACS-010759 in the
presence of induced or constitutive NOTCH1 signaling. We,
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therefore, propose that the synergy of OxPhos-i and VXL chemotherapy will effectively target both drug-resistant pre-LSCs
and bulk NOTCH1-dependent leukemic cells. Supporting the link
between mutation of the NOTCH1 oncogene and OxPhos activity, gene expression analysis from two independent patient
cohorts demonstrated enrichment of OxPhos related genes in the
transcriptome of NOTCH1-mutated T-ALL. Further, DepMap
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Fig. 6 VXL and IACS-010759 induce profound metabolic damage in vivo and leads to improvement of tumor burden reduction and overall survival in
PDX models in vivo. a MS Heatmap of metabolites in BM of mice transplanted with NOTCH1-mutated PDX80 after 12 h of treatment with vehicle, IACS010759, VXL, or the combination of IACS-010759 and VXL (n = 2). b CyTOF heatmap of spleen samples from PDX80 model treated with vehicle, IACS010759, VXL, or the combination of IACS-010759 and VXL (n = 2). c CyTOF UMAP for CD45, CD3, CD5, CD7 and Ki67 markers in spleen samples from
PDX80 model treated with vehicle, IACS-010759, VXL, or the combination of IACS-010759 and VXL (n = 2). d Gene expression analysis of spleen samples
from PDX80 model after treatment with the combination of IACS-010759 and VXL compared to vehicle treatment. e Leukemic engraftment (% of human
CD45+ leukemia cells) in spleen at day 5 of treatment with vehicle, VXL, IACS-010759, or the combination of IACS-010759 and VXL, as measured by FL
in 3 PDX models (from left to right: PDX D115, PDX CU76, PDX 80) (mean ± SD, n = 4 individual mice per treatment arm); one-way ANOVA; *p = 0.01;
**p = 0.0016; ***p = 0.0002, ****p < 0.0001. f Tumor burden development in 3 PDX models (from left to right: PDX D115, PDX CU76, PDX 80) measured
as weekly detection of circulating human CD45+ cells in peripheral blood (PB) and expressed as percent of normalized human to sum of human and
murine CD45+ cells in mice undergoing treatment with vehicle, IACS-010759 (5 mg/kg once daily, 5 days on/2 days off), VXL (once weekly), or the
combination of IACS-010759 and VXL (mean ± SD, n = 10 mice per treatment arm for PDX D115 and PDX CU76 and n = 8 mice per treatment arm for PDX
80). g Kaplan–Meier survival curves of mice transplanted with PDX models (from left to right: PDX D115, PDX CU76, PDX 80) and treated with vehicle,
IACS-010759, VXL, or the combination of IACS-010759 and VXL (n = 8). Treatment was initiated once the level of circulating leukemia cells in PB reached
0.5–1%; the timeframe of treatment is labeled by the yellow windows on the graphs. log-rank test: ***p < 0.0006 ****p < 0.0001.

dependency analysis and metabolic analysis by Seahorse technology indicated stronger OxPhos dependency and higher oxygen
consumption rates in NOTCH1-mutated cells compared to wt
counterparts. This evidence is in line with data that demonstrated
a dependency on ETC upon phenformin and mitochondriatargeted antioxidant MVE treatment in T-ALL Jurkat cells25,40.
Targeting mitochondria in T-ALL is supported by mechanistic
studies with a few agents (avicin, ABT-737, mitoTEMPO and
oligomycin), but the search for compounds eligible for translational studies is still ongoing. We provide evidence that OxPhos
dependency in NOTCH1-mutated T-ALL impacts ATP production and impairs proliferation. As previously demonstrated for
AML, OxPhos-i with IACS-010759 blocked mitochondrial
activity in T-ALL and exhibited potent antileukemic activity as
monotherapy in vitro.
It should be noted that IACS-010759 also impacted viability
and reduced OCR of NOTCH-wt cells compared with healthy
lymphocytes. Although not studied here, alternative mechanisms,
in addition to NOTCH1 gene mutation, are known to activate
NOTCH signaling in T-ALL10–12; and while metabolic phenotypes described in this study are most prominent in NOTCHmutated cells, OxPhos clearly contributes to metabolic ﬁtness of
NOTCH1 unmutated cells. In line with data reported for IACS010759 in AML and for phenformin and MB1-4748 in T-ALL,
comprehensive metabolomic studies revealed that IACS-010759
caused an energetic crisis by depletion of ATP and NAD/NADH
ratio, conﬁrming on-target effects, with blockade of RNA and
DNA synthesis through depletion of other NTPs. At the proteomic and transcriptomic levels, IACS-010759 induced AMPK,
Akt, and DNA damage pathways, with further activation of glycolytic enzymes in vitro and activation of AMPK and DNA
damage in vivo. We also demonstrated ROS induction, redox
imbalance and DNA damage upon complex I inhibition in T-ALL
cells, yet these did not translate into apoptosis, indicating the
ability of T-ALL cells to cope with the mitochondrial blockade.
Nevertheless, IACS-010759 demonstrated antileukemic activity
in vivo delaying a progression and signiﬁcantly extending survival
in a murine model of Notch1-mutated T-ALL and human
NOTCH1-mutated PDX models.
To dissect mechanisms of metabolic compensation, we
examined the glycolytic capacity of T-ALL samples. Of note, we
observed that while all T-ALL cells upregulate glycolysis, the
level of upregulation is strongly dependent on NOTCH1-status,
whereby NOTCH1-mutated cells exhibited a lower capacity to
utilize glycolysis upon OxPhos blockade. Instead, IACS-010759
caused a strong reduction of TCA intermediates α-KG, succinate, oxaloacetate, and citrate, and a moderate reduction of
fumarate and malate. In parallel, we found a profound change

in the α-KG/citrate ratio, indicating compensatory reprogramming through recruitment of glutamine reductive metabolism.
This was supported by nutrient depletion assays, together with
Seahorse and SIRM, which indicated that leukemic cells utilize
glutaminolysis as a source of energy to fuel the TCA cycle and
recruit reductive metabolism of glutamine to cope with metabolic stress under OxPhos-i. We demonstrated that activation of
reductive glutamine metabolism reduced the efﬁcacy of IACS010759 as a single agent, allowing cells to escape the complex I
blockade. These ﬁndings are consistent with the previously
reported results demonstrating that glutamine sustains the TCA
cycle in T-ALL29,49, and resembles the reported reliance on Gln
metabolism observed following FLT3 inhibitor treatment in
AML50–53. This ﬁnding was further supported by transcriptomic analyses demonstrating enrichment of glutaminerelated signatures in NOTCH1-mutated T-ALL. Notably,
Herranz et al. identiﬁed T-ALL as a glutaminolysis-dependent
disease showing that the blockade of glutamine metabolism in
T-ALL led to autophagy induction29, while in the study of
Nguyen et al. glutamine depletion triggered apoptosis in T-ALL
cells49. Altogether, our work provides strong evidence that
T-ALL cells have a unique vulnerability related to both OxPhos
and glutaminolysis.
To exploit this metabolic reprogramming therapeutically, we
examined dual inhibition of OxPhos and glutaminolysis. We
demonstrated that the genetic silencing of GLS in combination
with complex I inhibition can eradicate NOTCH1-mutated TALL, producing a similar extension of survival as reported direct
co-targeting Notch by γ-secretase inhibitor29. Given potential
challenges of the combinatorial use of two novel small molecules
in clinical trials, we utilized amino-acid depletion with L-asparaginase, known to have GLS-inhibitory activity. In aggressive
NOTCH1-mutated human PDX-T-ALL models, the L-asparaginase-containing VXL regimen, in combination with IACS010759, led to the metabolic and transcriptional collapse of
T-ALL cells resulting in a signiﬁcant reduction in tumor burden
and prolonged survival. A recent report demonstrated enhanced
combinatorial anti-tumor activity of ETC inhibition with dietary
asparagine restriction with asparaginase, through depletion of
exogenous asparagine that communicates active respiration to
ATF4 and mTORC154. While it remains to be seen if similar
mechanisms are operational in leukemia, the synergy observed in
our study could be broadly applicable to tumors beyond
NOTCH1-mutated ALL.
In summary, our ﬁndings provide a comprehensive understanding of the role of oxidative phosphorylation and metabolic
reprogramming in T-ALLs and offer a feasible translational
strategy of OxPhos inhibition in clinical trials.
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Table 1 Panel of cell lines used in the study.
Cell line

JURKAT
PF-382
1301
TALL-1
LOUCY
P12ICHIKAWA
MOLT-3
MOLT-4
CCRF-CEM
KOPT-K1
SUP-T1
MOLT-16
DND-41
ALL-SIL
HPB-ALL

NOTCH1 status

Table 2 Patient samples used in the study.

Glucocorticoid
sensitivity

Gamma
secretase
inhibitor
sensitivity

Mutation
Mutation
Mutation
Wild type
Wild type
Mutation

Resistant
Resistant
Sensitive
Resistant
Resistant
Sensitive

Resistant
Resistant
Resistant
Sensitive
Resistant
Resistant

Mutation
Mutation
Mutation
Mutation
Wild type
Wild type
Mutation
Mutation
Mutation

Resistant
Resistant
Sensitive
Resistant
Resistant
Sensitive
Sensitive
Sensitive
Resistant

Resistant
Resistant
Resistant
Sensitive
Sensitive
Resistant
Sensitive
Sensitive
Sensitive

Methods

UPIN

WBCs

% Blasts

NOTCH1 status

Other mutations

6661738

4.6

50

Mutation

6666190
6506670

29.5
24.2

95
69

Mutation
Mutation

6759914
6241832
6818814
6818752
6070472
6033966
4081030
4186482
6126932

102
2.3
76.8
31.5
1.7
23
31
81
100

53
60
87
73
40
88
93
39
92.7

Mutation
Mutation
Mutation
Wild type
Mutation
Wild type
Mutation
Mutation
Wild type

SUZ12, FBXWT,
KRAS, WT1
CEBPA, NRAS
PTEN, SUZ12, TET2,
U2AF1, WT1
JAK3, FBXW7, PHF6
EZH2, WT1, NF1, IL7R
IL7R
NRAS
KRAS
TP53
TP53
EZH, KRAS

UPIN unique physician identiﬁcation number, WBC white blood cell.

Table 3 PDX samples used in the in vitro and in vivo studies.
PDX ID

NOTCH1 status

PDX D115
PDX 12780
PDX CU178
MDX
PDX CU76
PDX 80
PDX 22330
PDX 4911
PDX 1921

Mutation
Mutation
Mutation
Mutation
Mutation
Mutation
Wild type
Wild type
Wild type

Cell lines, primary T-ALL samples, and healthy T-lymphocytes. The T-ALL cell
lines: JURKAT, PF-382, 1301, TALL-1, LOUCY, P12-ICHIKAWA, MOLT-3,
MOLT-4, CCRF-CEM, SUPT1 and KOPT-K1 were obtained initially from ATCC
were maintained at an internal core facility of Institute of Science in Cancer
MDACC and authenticated by short tandem repeat DNA ﬁngerprinting in February 2016. MOLT-16 (ACC 29), DND-41 (ACC 525), ALL-SIL (ACC 511), and
HPB-ALL (ACC 483), were purchased from DSMZ in March 2019. MS5 and MS5DL4 stroma cell lines: Mouse stromal MS5 cells were kindly provided by K. Mori
(Nagata University, Japan); VSV-G–producing cells transfected with the human
DLL4 cDNA (MHS4426-98361330, GE Healthcare) were used for gene transduction in MS5 cells (48 h). All used leukemia cell lines are summarized in Table 1.
Cell lines were maintained if not otherwise speciﬁed in RPMI-1640 medium with
2 mM Glutamine (SIGMA) containing 10–15% fetal calf serum and 1% penicillinstreptomycin (Life Technologies Laboratories).
Buffy coats were obtained from healthy blood donors provided by MD
Anderson Blood Bank. Healthy bone marrow (BM) samples, BM and peripheral
blood (PB) samples from T-ALL patients were collected during routine diagnostic
procedures. Samples were collected after written informed consent was obtained
from all patients and donors and was performed under the research protocols
PA13-1025 (Targeting metabolic pathways in leukemia, for ALL), LAB02-295 and
LAB04-0249 for healthy bone marrow and buffy coats from healthy blood donors,
in accordance with the University of Texas MD Anderson Cancer Center
Institutional Review Board regulations under the Declaration of Helsinki
principles. The research protocols were approved by the respective Institutional
Ethics Committees.
Mononuclear cells were separated by Ficoll-Hypaque (Sigma-Aldrich) density
gradient centrifugation. CD3+ T-lymphocytes were derived from buffy coats by
CD3+ magnetic beads isolation (Stem Cell Technology). Primary samples were
maintained in QBSF medium containing 20% fetal calf serum (Gemini BioProducts) and 1% penicillin-streptomycin (Life Technologies Laboratories). Patient
characteristics are shown in Table 2. All cells were grown at 37 °C in a humidiﬁed
atmosphere containing 5% carbon dioxide. D115 T-ALL PDX cells were kindly
provided by Dr. Patrick Zweidler McKey. PDX CU76, PDX 12780, PDX CU178,
PDX 2230. and murine T-ALL model (MDX) were kindly provided by Dr Adolfo
Ferrando. PDX 4911 and 1921 were kindly provided by Dr. Daniel Lacorazza.
PDX80 was generated in our lab from cells derived from a patient sample with the
patient’s written consent. The characteristics of the PDXs are shown in Table 3.

range of 10 drug concentrations was tested for each cell line to compute a curvefree area under the dose–response curve (AUC) based on linear interpolation of the
10 data points using a baseline of 0 (=100% inhibition) and a maximum of 10055.
The AUCs generated for each cell line were further summarized based on NOTCH1
status.
To evaluate the impact of glutamine, glucose and pyruvate on ATP production,
the cells were growing in RPMI1640 media without glutamine or glucose
purchased from MP Biomedicals (no nutrients), that were supplemented with
either 2 mM Gln, Glc at 5 mM or Pyr only at 1 mM; or with combination of these
nutrients. Data were normalized to values obtained from triple supplemented
media (Glc+Gln+Pyr). The results of ﬁve independent experiments were analyzed
and presented as average ±SD.
To evaluate the synergistic effects of IACS-010759 with CB-839, vincristine,
dexamethasone and L-asparaginase, cells were incubated in RPMI1640 (SIGMA)
media supplemented with 2 mM glutamine. The Matrix of 10×10 was created for
each combination and evaluated by CTG after 96 h of incubation. For synergy
evaluation in combination with CB-839, IACS-010759 was used in the range of
0–123 nM, vincristine (MP Biomedicals) was used in the range of 0–50 ng/mL,
dexamethasone (Sigma) in the range of 0–370 nM, and L-asparaginase from E. Coli
(Sigma; Cat. Nr A3809) was used in the range of 0–5 IU/ml. For synergy evaluation
in combination with VXL, IACS-010759 was used in the range of 0–50 nM,
vincristine was used in the range of 0–5 ng/mL, dexamethasone in the range of
0–50 nM, and L-asparaginase in the range of 0–0.5 IU/ml. The results of ﬁve
independent experiments were collected, processed, and visualized for synergy
evaluation using COMBENEFIT software56.

Cell viability assay. ALL-SIL, CCRF-CEM, DND-41, HPB-ALL, JURKAT,
LOUCY, MOLT-3, MOLT-4, SUP-T1, PF-382, and TALL-1 cells, CD3+
T-lymphocytes derived from healthy donors or bone marrow cells derived from
healthy donors were plated at a density of 10,000 cells/well in complete RPMI-1640
(SIGMA) supplemented with 10% fetal calf serum and subjected to treatment with
IACS-010759 (IACS, MD Anderson Cancer Center) at doses ranging from 0 to
123 nM for 96 h and CB-839 at doses ranging from 0 to 30 μM, creating a 10 × 10
matrix of treatment. CD3+ T-lymphocytes were additionally tested on DLL4
coated plates described in detail in DLL4 assay section and treated with IACS010759. Each experiment was performed independently 3–5 times. Viable cell
numbers were measured by quantifying ATP using a CellTiter-Glo Luminescent
Cell Viability Assay (Promega). Dose-response curves were analyzed using a curve
ﬁtting routine based on nonlinear regression to compute the IC50 value. The same

Evaluation of cell numbers, apoptosis, and ROS. The T-All cell lines ALL-SIL,
CCRF-CEM, DND-41, HPB-ALL, JURKAT, LOUCY, MOLT-3, MOLT-4, SUP-T1,
PF-382, and TALL-1 and CD3+ T-lymphocytes derived from healthy donors, or
bone marrow cells derived from healthy donors were plated at a density of 0.2 ×
106 cells/mL in complete RPMI-1640 supplemented with 10% fetal calf serum and
then treated with DMSO (control); IACS-010759 at concentrations of 1 nM, 5 nM,
10 nM, 30 nM, or 100 nM for 96 h; or CB-839 at 1 μM or VXL for 96 h. The effect
of IACS-010759 treatment on cell number and apoptosis was evaluated by Annexin
V (APC)-DAPI assay, after 96 h of exposure of the cells to the compound. The
effect of IACS-010759 on ROS levels in viable cells was evaluated by staining cells
with H2DCFDA. Brieﬂy, after 96 h of drug treatment, cells were collected and
washed twice in Annexin V binding buffer and resuspended in 100 μL of Annexin
V binding buffer with Annexin V-APC antibody (BD Bioscience) at a
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concentration of 1 μL/100 μL and H2DCFDA at a 1:1000 dilution and incubated in
the dark at room temperature (RT) for 30 min. Cells were then washed with
Annexin V binding buffer and resuspended after spinning in 300 μL Annexin V
binding buffer containing DAPI and counting beads (Invitrogen) at 5 μL/300 μL.
All conditions were run in triplicate and evaluated with Kaluza ﬂow cytometry (FL)
software or FlowJo software. The percentage of Annexin V-positive events was
normalized to that in DMSO-treated controls and presented as the percentage of
speciﬁc apoptosis, calculated as: (% Annexin V-positive cells in the sample−%
Annexin V-positive cells in the control)/(100−% Annexin V-positive cells in the
control) × 100. The number of living cells (DAPI-negative cells) was normalized to
that in DMSO-treated controls. The mean ﬂuorescence intensity of H2DCFDA,
indicating ROS level, was evaluated in DAPI-negative, Annexin V-negative cells
and normalized to that of DMSO-treated cells.
Niche-based assay for pre-LSCs. The niche-based assay was designed to sustain
optimal pre-LSC survival ex vivo by mimicking physiological NOTCH1 signal
strength and by adding KIT and FLT3 ligands and interleukin (IL)-7. Mouse
MS5 stromal cells expressing or not expressing optimal levels of human DL4 were
seeded in 96-well plates in the complete T-cell medium containing FLT3 ligand
(5 ng/mL), KIT ligand (20 ng/mL), and IL-7 (5 ng/mL) (R&D Systems). The following day, puriﬁed CD4−CD8− thymocytes from 5–6-week-old preleukemic
transgenic mice LMO1tg or SCLtgLMO1tg were co-cultured on MS5 or MS5-DL4
monolayers for another 24 h prior to the addition of IACS-010759 at the indicated
concentrations. Pre-LSC viability was determined after 72 h of drug treatment
using multiparameter ﬂow cytometry (Thy1+CD4−CD8−CD25+CD44−) with the
VivaFix cell viability assay (BioRad) and the LSRII ﬂow cytometer equipped with a
high-throughput-screening module (BD Biosciences)57. Data acquisition was performed with a FACS Celesta ﬂow cytometer equipped with a high-throughputscreening module (BD Biosciences). (Thy1+CD4−CD8−CD25+CD44−) Pre-LSC
viability was normalized to that of control cultures containing the solvent alone
(DMSO)47.
DLL4 assay. Human DLL4 Fc Chimera Recombinant Protein (Thermo Fisher),
was diluted in chilled phosphate-buffered saline (PBS) at 10 μg/mL as
recommended58, and 50 μL/well was coated in standard tissue-culture 96-well
plates overnight at 4 °C. Wells were washed once with PBS before seeding cells to
remove any unbound ligand from the wells. Healthy donor T-lymphocytes isolated
from PBMCs as described in “Methods” were then suspended at the density of
30,000/well and seeded in the DLL4 coated plate or just washed with sterile PBS
plates and further submitted to treatment with IACS-010759 at the concentration
range 0-123 nM.
The same coating approach scaled up to 24 well format was used further for
viable cell number/apoptosis evaluation by FL and for seahorse assay. Here shortly
T-lymphocytes were seeded in complete RPMI1640 either on DLL4 coated wells or
once PBS washed wells and subjected to treatment with IACS-010759 at the
concentration of 10 nM in triplicated (for FL). The viability changes were then
evaluated after 72 hr of incubation by FL. The impact of combined DLL4 and
IACS-010759 on cell metabolism was evaluated after 24 h incubation by seahorse
assay as described in the “Method” section for Seahorse assay.
Colony-forming unit assay. Healthy donor-derived fresh bone marrow cells were
subjected to treatment with: DMSO, 10 nM IACS-010759, 1 uM CB839, VXL or a
combination of IACS-010759/CB839 or IACS-010759/VXL for 24 h. Cells were
then collected and counted, followed by preparing the suspension of 1×105 cells in
400 µl of complete RPMI-1640 (SIGMA), supplemented with 10% FBS in 15 ml
Falcon tubes. 4 ml of MethoCult™ GF M3434 (Stem Cell Technologies; cat. 3434)
was transferred to each Falcon tube using a 5 ml syringe with 18g1½ gauge needle
and suspended in the methylcellulose by vortexing for 1 min. After 15 min of rest,
3 ml of methylcellulose were distributed between 3 bottom-grinded culture plates
with aimed density of 2.5 × 104 cells/1 ml Methylcellulose/well) using a 3 ml syringe with 18g1½ gauge needle. Cells were allowed to grow for 12–14 days before
colonies were manually counted.
Analysis of OxPhos activity, glycolysis activity, and ATP using Seahorse
technology. To characterize the metabolic phenotype of T-ALL cells,
T-lymphocytes or bone marrow cells derived from healthy donors, and to evaluate
the impact of inhibition of complex I on mitochondrial metabolism, we measured
OCR and ECAR in sets of T-ALL cell lines, patient samples, healthy T-lymphocytes, hBM cells and PDX samples ex vivo using the Seahorse Mito Stress Test,
Glycolysis Stress Test, and ATP Rate Assay (Agilent Technologies). Each of the
following cell lines: ALL-SIL, CCRF-CEM, DND-41, HPB-ALL, JURKAT, LOUCY,
MOLT-3, MOLT-4, SUP-T1, PF-382, and TALL-1, as well as CD3+ T-lymphocytes
and treated with IACS-010759 at doses of 0–123 nM for 4 h in complete RPMI1640 media, followed by the appropriate Seahorse test for the speciﬁc scientiﬁc
question.
In brief, cells were washed 2 times with phosphate-buffered saline (PBS) and
resuspended in prewarmed (37 °C) Seahorse Basal Medium supplemented with
1 mM pyruvate, 2 mM glutamine, and 5 mM glucose, pH 7.4 (for Mito Stress Test);
in prewarmed Seahorse Basal Medium supplemented with 2 mM glutamine, pH 7.4
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(for Glycolysis Stress Test); or in buffered RPMI-1640 Seahorse Basal Medium
supplemented with 1 mM pyruvate, 2 mM glutamine, and 5 mM glucose (for ATP
Real-Time Rate Assay). Next, 175 μL of cells suspended at a density of 2 million/
mL were plated in at least 4 replicates on 96-well Seahorse Cell Culture plates. To
allow cells to attach to the bottom of the plates and create cell monolayers, the
plates were precoated with Cell-Tak (Corning) according to the manufacturer’s
instructions. Once plated, cells were subjected to gentle centrifugation at RT for
4 min, then at 1500 rpm without a break, and then the centrifugation was repeated
in the opposite direction.
OCR and ECAR were determined using a Seahorse XFe96 analyzer according to
the manufacturer’s instructions. The OCR and ECAR values were obtained at
baseline (3 initial measurements) and after the injections of Seahorse XF Mito
Stress Test Kit reagents: oligomycin (ﬁnal concentration 1.5 μM), FCCP (ﬁnal
concentration 1.0 mM), and antimycin/rotenone (ﬁnal concentration 0.5 μM);
Glycolysis Stress Test Kit reagents: glucose (ﬁnal concentration 10 mM),
oligomycin (ﬁnal concentration 1.5 μM), and 2-deoxy-D-glucose (ﬁnal
concentration 50 mM); or ATP Real-Time Rate Assay Kit reagents: oligomycin
(ﬁnal concentration 1.5 μM) and rotenone/antimycin (ﬁnal concentration 0.5 μM).
All measurements were carried out by the Mito Stress Test Generator, Glycolysis
Stress Test Generator, or ATP Real-Time Rate Assay Generator (Agilent
Technologies), as appropriate, and normalized to cell number after the assays. The
data collected for basal and maximal OCR and ECAR after exposure to the range of
drug concentrations were plotted to calculate the IC50 values. AUC values were
generated for each examined cell line and T-lymphocytes by NOTCH1-status.
Further examination of OxPhos modulation by CB-839 and VXL was carried out
by Mito Stress Test assay.
Analysis of genome-wide chromatin occupancy by NOTCH1 in pre-LSCs.
Genome-wide chromatin occupancy by NOTCH1 was computed from chromatin
immunoprecipitation-DNA sequencing data reported by Wang et al. for the
murine T-ALL cell lines G4A2 and T6E35. The gene list was further restricted to
those in which NOTCH1-bound peaks were present within 2 kb of their transcription start sites as previously described36. The expression of NOTCH1-bound
genes within the OxPhos pathway during normal thymocyte differentiation was
analyzed using ultra-low input RNA-seq data from the Immunological Genome
Project IMMGEN (http://www.immgen.org/)59. Notch1-induced gene expression in
DP T-cells was obtained by analysis of microarray data from puriﬁed murine
CD4+CD8+GFP+ cells expressing or not expressing the Notch1 oncogene (ICN,
GSE12948) at the preleukemic (2 weeks) and leukemic (6 weeks) stages (https://
www.ncbi.nlm.nih.gov/geo/geo2r)60. Analysis of differentially expressed genes for
GSEA and heatmaps (http://bioinformatics.sdstate.edu/idep/, https://www.
gseamsigdb.org/gsea/index.jsp) was performed as described previously36.
RNA variant calling pipeline. To detect short variants in RNA-seq, we ran the
GATK RNA-seq variant calling pipeline (https://gatk.broadinstitute.org/hc/en-us/
articles/360035531192-RNAseq-short-variant-discovery-SNPs-Indels-). We
obtained Fastq ﬁles of RNA-seq data from the public T-ALL dataset
(PRJNA572580; GEO Accession: GSE137768)33. Quality control and data preprocessing were done with fastp (version 0.20.0)61. We used the STAR aligner
(version 2.6.0b) in two-pass mode aligned to the reference genome b37
(Homo_sapiens_assembly19.fasta)62. Duplicate reads were marked and removed
by Picard MarkDuplicates (version 2.9.0). GATK (version 3.7) SplitNCigarReads
was used to split and trim reads to remove any overhangs into introns. Base quality
recalibration was performed with GATK (version 4.1.0.0), BaseRecalibrator, and
APPlyBQSR. To correctly handle the splice junctions, the GATK Haplotypecaller
was used to perform variant calling with a minimum phred-scaled conﬁdence
threshold of 20.0. We removed known single-nucleotide polymorphisms using
dbSNP (version 138). We ﬁltered variant call quality based on Fisher strand values
greater than 30.0 and Qual by Depth values below 2.0 with GATK Variant Filtration. To annotate gene variants, we used ANNOVAR and combined each
output table.
DepMAP Crispr analysis. Genome-scale CRISPR-Cas9 screen result was obtained
at the DepMap Portal (https://depmap.org/portal/achilles) with all data (raw read
counts to processed gene effect scores) available in the 19q4 DepMap dataset
(FigShare: https://ﬁgshare.com/articles/dataset/DepMap_19Q4_Public/11384241/
3)63–65. To determine the genetic dependencies that were enriched in T-ALL cell
lines (HSB-2, PF-382, and SUP-T1), we utilized linear-model analyses from the
limma R package66 to perform a two-tailed t-test for the difference in the distribution of gene effect (dependency) scores in T-ALL cell lines compared to other
cell lines screened. Statistical signiﬁcance was calculated as a q-value derived from
the p-value corrected for multiple hypothesis testing using the Benjamini &
Hochberg method67.
RNA-Seq. PF-382 and SUP-T1 cells were collected for RNA-seq when cells were
harvested for mass spectrometry (MS) analysis. Cells from PDX80 were collected
following short treatment studies with IACS-010759 and VXL as described. Total
RNA was extracted from 4 × 106 cells using the RNeasy Mini Kit (Qiagen; cat.
74104). RNA concentration was determined by a NanoDrop
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2000 spectrophotometer (Thermo Fisher Scientiﬁc), and RNA quality was assessed
with an Agilent Bioanalyzer. Approximately 100 million reads per sample were run
on an Illumina Nextseq 500 system using 75 × 75 paired end (PE) reads for
stranded whole-transcriptome sequencing. Raw sequencing reads were pseudo
aligned using Kallisto v0.44.059 with 30 bootstrap samples to a transcriptome index
based on the human GRCh38.92 release (Ensembl). Abundance data were further
analyzed with Sleuth v0.30.060 using models with covariates for condition. Genelevel abundance estimates were calculated as the sum of transcripts per million
(TPM) mapped to a given gene. The data have been deposited in the NCBI’s Gene
Expression Omnibus (GEO) database (GSE167305) (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE167305).
NetBID analysis. TPM-normalized count matrices from 3 cell lines (PF-382, SUPT11, and PDX80), were log2 transformed and ﬁltered for genes that were not
detected in all samples (i.e., row sums > 0). To reduce the noise introduced by
genes with low counts, we used an interquartile range method to rank the genes
and selected the top 50% of the highly variable genes to run NetBID analysis on
each cell line independently. This resulted in ~18 K genes for downstream analysis
across 39 samples from the 2 cell lines PF382 and SUPT1 and 3 single drug-treated
and 2 combination-treated cell lines (Vehicle, IACS-010759, CB-839, VXL, IACS010759 + CB-839, and IACS-010759 + VXL) and 2 organs (spleen and BM) of
PDX model T-ALL PDX80 treated with (Vehicle, IACS-010759, VXL, and IACS010759 + VXL). Next, we merged all the gene sets from the Molecular Signatures
Database (MsigDB) (http://www.gsea-msigdb.org/gsea/msigdb/) and calculated
pathway activity in each sample using the mean expression level of genes in the
gene sets; we then performed differential activity analysis at the pathway level.
Signiﬁcant pathways were selected at p < 0.05 or p < 0.1. We also applied the
NetBID algorithm (https://github.com/jyyulab/NetBID) to the T-ALL RNA-seq
data from the TARGET project and the COG AALL1231 trial to compare
NOTCH1-mutant to -wild type samples.
Mass spectrometry analysis of cell lines and PDX derived cells. The NOTCH1mutated T-ALL cell line PF-382 and the NOTCH1-wt T-ALL cell line SUP-T1 were
cultured in T75 ﬂasks at a density of 1 million cells/mL and then treated with
DMSO, IACS-010759 (10 nM), CB-839 (1 μM), IACS-010759 + CB-839, VXL
(1 ng/ml of vincristine, 10 nM dexamethasone, 0.1 IU/ml of L-asparaginase), or
IACS-010759 + VXL, in RPMI-1640 media (MP Biomedicals) supplemented with
10% dialyzed fetal bovine serum (FBS; Life Technologies) with Gln and Glc; RPMI1640 media supplemented with 10% dialyzed FBS with 13C515N2-glutamine
(Cambridge Laboratories) and unlabeled Glc; or RPMI-1640 media supplemented
with 10% dialyzed FBS with unlabeled Gln and 13C6-glucose (Cambridge
Laboratories). The NOTCH1-mutated cell line PF-382 was collected after 12 h of
treatment, and the wild-type NOTCH1 cell line SUP-T1 was collected after 24 h.
Each condition was repeated in triplicate. After treatment, cells were centrifuged in
50 mL Falcon tubes, and cell pellets were washed twice in cold PBS. Cells were
recounted, and cell pellets were ﬂash-frozen in liquid nitrogen for further analysis.
For ex vivo metabolomic analyses, spleen and BM cells collected after organ
harvesting were ﬁrst subjected to engraftment analysis by FL, followed by counting
and ﬂash freezing in liquid nitrogen. Cell pellets were then subjected to mass
spectrometry (MS) analysis. The metabolites were extracted using a modiﬁed
Bligh-Dyer procedure by adding water, methanol, and chloroform in equal
volumes (1:1:1). The resulting solution was vortexed vigorously and stirred at
1000g for 10 min, then centrifuged at 2119g for 20 min at 4 °C. The polar fraction
was collected in Eppendorf tubes, evaporated to dryness in a Centri Vap
refrigerated vacuum concentrator (Labconco) at 4 °C, and resuspended in 180 µL
ultrapure water and 20 µL of internal standard solution, as previously
described68,69. The 200-µL solution was ﬁltered through a Nanosep 3 K
ultracentrifugal device (Pall Co.) at 6010 rpm for 20 min at 4 °C70. The resultant
ﬁltrate was poured into liquid chromatography (LC) vial and stored at −20 °C until
LC-MS analysis. Metabolomic analysis of polar fractions was performed on a
Hybrid quadrupole-Orbitrap mass spectrometer (Q Exactive, Thermo Scientiﬁc)
with a Thermo Scientiﬁc Accela 1250 ultra-high-performance LC system with an
electrospray ionization source, simultaneously operating in positive/negative
polarity-switching ionization mode. Metabolites were chromatographically
separated using a Kinetex C18 150 × 2.1 mm (2.6 μm, 100 Å) column
(Phenomenex) with gradient elution of 0.2% formic acid in water (A) and
methanol (B) at a ﬂow rate of 150 µL min−1 within 30 min. The gradient elution
was programmed as follows: 0–4 min, 2% B; 4–14 min, 2–80% B; 14–15 min,
80–98% B; 15–20 min, 98–98% B; 20–25 min, 98–2% B, equilibration time 5 min.
Detection of metabolites was performed in full MS mode under the following
conditions: spray voltage, 4.0 kV; capillary temperature, 300 °C; sheath gas, 50
(arbitrary units); auxiliary gas, 10 (arbitrary units); microscans, 1; AGC target, 3e6;
maximum injection time, 200 ms; mass resolution, 70,000 full-width halfmaximum; m/z range, 50–750. To ensure mass accuracy below 5 ppm, the MS
detector was calibrated prior to analysis using commercial calibration solutions.
The LC-MS platform was controlled by XCalibur 2.2 software (Thermo Scientiﬁc).
A quality control sample, representing the equivalent concentration of all samples,
was prepared to control possible instrumental error (drift) in data acquisition and
was run once every ﬁve samples71. All raw MS datasets were processed using Sieve
2.2 (Thermo Fisher Scientiﬁc), and features with a coefﬁcient of variation lower
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than 25% in the quality control samples were considered for further analysis. Peaks
were scaled according to probabilistic quotient normalization, and features were
then mined against an in-house database of accurate masses and retention times
generated in our laboratory using the IROA 300 MS Metabolite Library of
Standards (IROA Technologies). In addition, databases of accurate masses taken
from the Kyoto Encyclopedia of Genes and Genomes and the Human Metabolome
database were also mined72,73. Raw data are deposited in Zenodo open access
repository (https://doi.org/10.5281/zenodo.6442444).
Mass spectrometry analysis of peripheral blood. A 10-µL whole blood sample
was collected through the retroorbital sinus of the mice and immediately combined
with 100 µL extraction solvent (ice-cold methanol:water = 80:20 with 10 µM d4citrate internal standard), vortex-mixed for 2 min, and centrifuged at 20,000g for
10 min at 4 °C. The supernatant was transferred into 1.5-mL snap-cap tubes, dried
using a Speedvac concentrator, and stored until further analysis. Upon analysis, the
dried pellets were reconstituted in 100 μL ultra-pure water and centrifuged at
20,000 g for 10 min at 4 °C. From the supernatants, 90 μL was transferred to
polypropylene autosampler vials. A 10-μL volume of extract was injected into the
ion chromatography (IC)-MS system without dilution. IC gradient and MS settings
were as previously described74. The IC-MS platform included a Thermo Scientiﬁc
Dionex ICS-5000+ capillary IC system with a Thermo IonPac AS11 250 × 2 mm 4
μm column. Data were acquired using a Thermo Orbitrap Fusion Tribrid Mass
Spectrometer under electrospray ionization negative ionization mode. The raw ﬁles
were then imported into Thermo Trace Finder software to extract chromatographic
peak areas for targets of interest. Peak areas were normalized using internal
standard peak areas. Raw data are deposited in Zenodo open access repository
(https://doi.org/10.5281/zenodo.6442444).
Ingenuity pathway analysis. The values measured for each metabolite were calculated as expression log ratios of the following: GLS−/GLS+, GLS+IACS-010759/
GLS+, and GLS−IACS-010759/GLS+ and uploaded to Ingenuity Pathway Analysis software (QIAGEN). The comparisons selected the most signiﬁcantly affected
canonical pathways.
siRNA transfection. NOTCH1-mutated T-ALL cell lines PF-382 and JURKAT
(1 × 105 cells per well) were seeded overnight. Negative control (NT-siRNA), KAG
or GAC GLS-siRNA was transfected with jetPRIME transfection reagent, according
to the manufacturer’s instructions (Polyplus). The following plasmids were used:
pHUSH puro D3; pHUSH puro KGA sh5; and pHUSH GAC sh3 (kindly provided
by Dr. Georgia Hatzivassiliou, Genentech). For further studies puromycine selected
cells were used. To induce knockdown of GLS, doxycycline at the concentration of
2 ug/ml was used. The detection of knockdown was evaluated at day 5 after
initiation of treatment with doxycycline. The cells with conﬁrmed knockdown were
subjected to evaluate viability (CTG), cell growth, Seahorse analysis of metabolic
changes with or without treatment with OxPhos inhibitor at the concentration of
10 nM, and to immunoblotting.
Immunoblotting. Cells (1–2 × 106 per well) were seeded overnight in 6-well plates.
Following treatment for the speciﬁed duration, total protein was extracted in
Laemmli buffer, fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene ﬂuoride membranes (Millipore
Sigma). After blocking with Li-COR Odyssey blocking buffer, the membranes were
incubated with primary antibodies overnight at 4 °C, washed, incubated for 2 h
with infrared ﬂuorochrome-conjugated secondary antibodies: Odyssey Irdye 680
RD anti-mouse and Odyssey Irdye 800 CW goat anti-rabbit, as appropriate. The
protein signal was visualized using a LI-COR Odyssey imaging system. The panel
of antibodies used for Immunoblotting is summarized in Supplementary Table 1.
CYTOF. Human T-ALL PDX 80 samples were collected from spleens. Samples
were initially barcoded and stained with metal-conjugated antibodies according to
Fluidigm’s protocols as described below. Brieﬂy, all antibodies were labeled with
heavy metals using Maxpar-X8 labeling reagent kits (Fluidigm DVS Sciences)
according to the manufacturer’s instructions and titrated to determine the optimal
concentration. For each mouse evaluated, 3 × 106 cells were aliquoted into separate
FACS tubes and washed twice with Maxpar PBS buffer (Fluidigm; cat. 201058). For
live/dead cell discrimination, cells were resuspended in 200 µL of 5 µM cisplatin
(Fluidigm; cat. 201064) for 1 min on an orbital shaker, followed immediately by 3
washes in Maxpar cell staining buffer (CSB; Fluidigm; cat. 201068). Cells were then
subjected for 10 min to ﬁxation in 1 mL of 1× Fix I buffer (Fluidigm; cat. 201065),
followed by 2 washes with 1× barcode perm buffer (Fluidigm; cat. 201057). Each
unique palladium barcode (Fluidigm; Cell-ID 20-Plex Pd Barcoding Kit, cat.
201060) was suspended in 100 µL of barcode perm buffer and immediately
transferred to cells in 800 µL barcode perm buffer. Cells were incubated with
barcodes for 30 min, then washed twice with 2 mL CSB. Barcoded cells were then
combined into a single tube for CyTOF staining. The staining factor was calculated
as the total number of barcoded cells/3 × 106 cells. Cells were blocked with 5 μL×
staining factor of anti-human Fc receptor binding inhibitor (eBioscience Invitrogen) in 45 µL × staining factor of CSB for 15 min at RT. An appropriate amount of
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Table 4 Panel of antibodies used for CyTOF staining.
Isotope/Metal

Marker

127I

S-phase
CD7
Caspase 3, cleaved
PARP, cleaved
p-AKT
p-STAT5(Y694)
CD34
p-4EBP1
β-catenin, active
p-H2AX, p-γ-H2AX
Notch-1
p21, WAF1/Cip1
p-p38 (180/182)
p-Histone H3
p-PI3K (p85/p55)
Cytochrome C
mTOR
c-Myc
p-AMPKα (T172)
HIF-1α
p-ERK1/2
Ki67
CD3
CD5
p-S6
Cyclin B1
Cisplatin
CD45 89Y

139La
142Nd
143Nd
144Nd
147Sm
148Nd
149Sm
150Nd
152Sm
153Eu
154Sm
156Gd
159Tb
160Gd
161Dy
162Dy
163Dy
164Dy
165Ho
167Er
168Er
170Er
174Yb
175Lu
176Yb
195Pt
89Y

Clone
CD7-6B7
D3E9
F21-852
M89-61
47
581
236B4
8E7
N1-431
MHN1-519
CP74
D3F9
HTA28
Polyclonal
7H8.2C12
Polyclonal
D84C12
40H9
Polyclonal
D13.14.4E
(Ki67) X8
UCHT1
L17F12
N7-548
GNS-1
HI30

surface antibody master mix (Table 4) was added directly to the tube and incubated
for 1 h at RT before 2 washes with CSB.
For intracellular staining, cells were dissociated in 1 mL of ﬁxation/
permeabilization buffer and incubated overnight at 4 °C, then washed twice with
2 mL of 1× permeabilization buffer. The supernatant from the ﬁnal wash was
discarded, and appropriate amounts of intracellular antibody master mix were
added to the residual permeabilization buffer and incubated for 1 h in the dark at
RT. For cell discrimination, a metallointercalator working solution (2 mL
Permeabilization Buffer, 125 nM iridium metallointercalator [Fluidigm; cat.
201103 A]) was added to the sample and incubated overnight at 4 °C. Cells were
washed with a minimum of 3 mL CSB, then again with 3 mL ddH2O with 0.1%
bovine serum albumin. Finally, cells were ﬁltered through a 35-µm ﬁlter and
resuspended in 100 µL ddH2O with 0.1% bovine serum albumin. The MD
Anderson Flow Cytometry and Cellular Imaging Core Facility prepared the
antibody cocktails and acquired data on a Helios CyTOF machine (DVS Sciences).
Data were ﬁrst demultiplexed by Fluidigm Debarcoder software. Individual
mass cytometry data ﬁles (.fcs) were then ﬁltered using FlowJo to remove the
normalization beads, debris, doublets, and dead cells. The remaining analysis was
performed in R (version 3.6.1, The R Foundation for Statistical Computing) using
the R packages ‘cytofkit’ and ‘ﬂowcore’75. Processed data were subjected to negative
value pruned inverse hyperbolic sine transformation and clustered based on the
PhenoGraph algorithm (k = 22) using all cell surface markers76. Dimensionality
reduction was performed using the uniform manifold approximation and
projection (UMAP) method77.

Animal studies. For the studies of pre-LSCs, all mouse lines were backcrossed onto
a C57BL/6J background for more than 12 generations to produce pSTIL-SCL
(SCLtg), Lck-LMO1 (LMO1tg), and Lck-NotchIC9 (Notch1tg) mice (NIAID/Taconic
Repository). Mice (male and female) were maintained separately in pathogen-free
conditions according to institutional animal care and use guidelines set by the
Canadian Council on Animal Care. At least 3 mice per genotype were used for
experimental work. For the studies of T-ALL, all experimental animal procedures
were approved by MD Anderson Cancer Center’s Institutional Animal Care and
Use Committee (IACUC). The study was compliant with all relevant ethical regulations regarding animal research. Animal studies were conducted at MD
Anderson’s animal facilities in accordance with the IACUC guidelines. Mice were
maintained in a pathogen-free environment with free access to food. 8-week-old
female C57BL/6 mice were purchased from The Jackson Laboratory and allowed to
acclimatize for 1 week before being irradiated with a sublethal dose of 400 cGy on
the day before T-ALL cell injection. To examine the impact of complex I inhibition
in a genetic model of glutaminase knockout, we used NOTCH1-induced T-ALL

Source

Catalog No.

Intracellular

Sigma
BioLegend
DVS-Sunnyvale
DVS-Fluidigm
BD
DVS-Fluidigm
BD
DVS-Fluidigm
EMD
BD
BioLegend
Sigma
DVS-Fluidigm
BioLegend
CST
Abcam
GenScript
CST
CST
Novus
DVS-Sunnyvale
DVS-Fluidigm
BioLegend
BioLegend
DVS-Fluidigm
BD
Sigma
DVS-Fluidigm

I7125-5G
343102
3142004A
3143011A
560397
3147012A
555820
3149005A
05-665
560443
352102
P1484
3156002A
641002
4228BF
ab13575
A01154
5605BF
2535BF
NB100-479
3167005A
3168001B
300443
364002
3175009A
554177
P4394
3089003B

NO
NO
YES
YES
YES
YES
NO
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
NO
NO
YES
YES
YES
NO

murine cells with tamoxifen-inducible conditional Gls knockout (Rosa26Cre-ERT2/+Glsf/f),
which were generated and kindly provided by Drs. Daniel Herranz and Adolfo Ferrando
(Columbia University). A total of 1 × 106 cells suspended in 100 μL sterile PBS were
injected into the tail veins of the female C57BL/6 mice29. Disease progression was
monitored weekly by retroorbital blood draws, and measurements of GFP+ leukemic
cells in the PB were normalized to the total amount of murine CD45+ cells, after
exclusion of DAPI+ (dead) cells. Once the leukemia cells were detectable in PB (day 7,
Figure S22A, B), mice were randomized into 2 treatment groups (n = 10 mice per
group). One group underwent conditional knockout of GLS by administration of 1 mg
tamoxifen over 5 consecutive days (GLS−), and the other was treated with corn oil
(GLS+). To measure the additive or synergistic effects of complex I inhibition, GLS− and
GLS+ mice were treated with either vehicle or IACS-010759 (7.5 mg/kg) (n = 5 mice per
arm) by oral gavage once daily on a schedule of 5 days on/2 days off starting at Day 7 up
to Day 68. Disease progression and response to treatment were measured by weekly
engraftment checks. Mice were euthanized when visible signs of clinical illness were
observed or weight loss of >20% was recorded. To measure the short-term impact of
complex I inhibition and glutaminase knockout, mice (n = 3 per treatment arm)
engrafted at a level of 5% of circulating leukemia cells in PB were subjected to the same
treatment regimen for 5 days, followed by mice euthanasia by cervical dislocation, organ
harvesting and measurement of circulating leukemia cells in PB and the level of leukemic
cell engraftment in the spleen, BM, and liver. Tissues collected after the treatment were
subjected to histopathological examination, and blood collected after treatment was
further subjected to MS analysis.
To examine the impact of complex I inhibition in combination with standardof-care chemotherapy, 8- to 10-week-old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/
SzJ (NSG) mice were purchased from The Jackson Laboratory (cat # 005557) and
allowed to acclimatize for 1 week. After irradiation on the day prior to injection,
each mouse was injected via the tail vein with 1.0 × 106 T-ALL PDX cells
suspended in 100 μL sterile PBS; the PDX models used were CU76, PDX D115, and
PDX80. Disease progression was monitored weekly by retroorbital blood draws,
and FL was used to monitor the percentage of human CD45 + cells normalized to
that of murine CD45+ cells after exclusion of DAPI+ (dead) cells. Treatment was
initiated at detection of 1% to 5% circulating leukemia cells in the blood (n = 10
mice per arm). IACS-010759 was administered via oral gavage once daily at 5 mg/
kg (5 days on/2 days off). Standard-of-care chemotherapy (VXL) was administered
intraperitoneal once per week, 8 h after administration of IACS-010759, for
4 weeks. VXL was used at a reduced dose of: dexamethasone (5 mg/kg), vincristine
(0.15 mg/kg); and L-asparagine (1000 IU/kg, approx. 25 IU/mouse). E. coli-derived
L-asparaginase was purchased from Elspar, Lundbeck, Deerﬁeld, IL, USA.
To measure the short-term impact of complex I inhibition on leukemia
metabolism and VXL sensitivity, mice engrafted at a level of 30–50% circulating
leukemia cells in PB were subjected to the treatment regimen above for 5 days
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(n = 4 mice per PD treatment arm). 12 h after the last dose of IACS-010759, mice
were euthanized by cervical dislocation, followed by harvest of PB, spleen, BM in
order to measure circulating leukemia cells in PB and the level of leukemic cells in
spleen and BM. Tissues of spleen, BM and liver collected after treatment were
subjected to histopathological examination, blood collected after treatment was
subjected additionally to MS analysis, and spleen cells collected after treatment
were ﬂash-frozen in liquid nitrogen for MS analysis and for RNA extraction
followed by RNA-seq, or frozen in 10% DMSO/90% fetal calf serum for further
CyTOF analysis.
Histopathology evaluation. Five-micron-thick sections of tissues were cut using
a Leica Microsystems cryostat, transferred onto Superfrost-Plus slides (Thermo
Fisher Scientiﬁc), and stained with hematoxylin and eosin (H&E). BM, spleen,
and liver tissue samples were further evaluated by pathologist, blinded to the
treatment groups, for determining the leukemic inﬁltration of tissues and
morphologic changes of hematopoiesis. Stained tissue slides were examined
microscopically using Olympus BX 41 microscope and by scanning the slides
with Aperio AT2 scanner and viewing the images with Aperio Image Scope
software.

2.

3.

4.

5.

6.
7.
8.
9.

Statistical analysis. Unless otherwise indicated, all calculations and statistical
analyses were carried out using GraphPad Prism software v. 7 or 8. Figure legends
indicate speciﬁc statistical analyses used and deﬁne error bars. Statistically signiﬁcant differences between 2 groups were assessed by unpaired Student’s t tests.
Ordinary one-way analysis of variance (ANOVA) was used to analyze more than 2
groups. Two-way ANOVA was used to analyze cell proliferation at multiple time
points. Results are expressed as mean ± SD (as noted in the ﬁgure legends) of at
least 3 independent experiments, and p values less than 0.05 were considered
statistically signiﬁcant. Survival analysis for in vivo studies was done using
Mantel–Cox and Gehan–Breslow–Wilcoxon tests.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

10.
11.

12.
13.

14.

15.

Data availability
All data supporting this study are provided in the manuscript or made publicly available.
ChIP-seq data published previously by Wang et al. were used for computation of
genome-wide chromatin occupancy by NOTCH1 and are available under accession code
GSE29600.
Ultra-low input RNA-seq data from the Immunological Genome Project IMMGEN
are available under accession code GSE100738 (http://www.immgen.org/).
Microarray data from puriﬁed murine CD4+CD8+GFP+ cells expressing or not
expressing the Notch1 oncogene at the preleukemic (2 weeks) and leukemic (6 weeks)
stages are available under accession code GSE12948 (https://www.ncbi.nlm.nih.gov/geo/
geo2r).
Genome-scale CRISPR-Cas9 screen result was obtained at the DepMap Portal
(33T33T https://depmap.org/portal/achilles33T) with all data (raw read counts to
processed gene effect scores) available in the 19q4 DepMap dataset (FigShare: https://
ﬁgshare.com/articles/dataset/DepMap_19Q4_Public/11384241/3).
RNA-seq data generated in this study have been deposited in the NCBI’s Gene
Expression Omnibus (GEO) database (GSE167305).
The gene sets from the Molecular Signatures Database (MsigDB) (http://www.gseamsigdb.org/gsea/msigdb/) were merged and used for pathway activity calculations using
NetBID in each sample using the mean expression level of genes in the gene sets.
Data may be accessed through the TARGET website at https://ocg.cancer.gov/
programs/target. The sequencing BAM and FASTQ ﬁles from TARGET RNA-seq are
accessible through the database of genotypes and phenotypes (dbGaP; http://www.ncbi.
nlm.nih.gov/gap) under accession number phs000218 (TARGET) and substudy speciﬁc
accession phs000464 (TARGET ALL Expansion Phase 2).
Fastq ﬁles of RNA-seq data from the public T-ALL dataset from the frontline
Children’s Oncology Group (COG) T-ALL clinical trial AALL1231 are deposited under
accession code (PRJNA572580; GEO Accession: GSE137768)
Metabolomics data are deposited in Zenodo open access repository (https://doi.org/10.
5281/zenodo.6442444)
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